REFERENCES
- Abali H., Oyan B., Koc Y., Kars A., Barista I., Uner A., Turker A., Demirkazik F., Tekin F., Tekuzman G., Kansu E. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. Am. J. Clin. Oncol. 2005; 28: 264–269, [PUBMED], [INFOTRIEVE], [CSA]
- Aeschlimann C., Kupfer A., Schefer H., Cerny T. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. Drug Metab. Dispos. 1998; 26: 883–890, [PUBMED], [INFOTRIEVE], [CSA]
- Agarwal D. P., Goedde H. W. Pharmacogenetics of alcohol metabolism and alcoholism. Pharmacogenetics 1992; 2: 48–62, [PUBMED], [INFOTRIEVE], [CSA]
- Agarwal D. P., von Eitzen U., Meier-Tackmann D., Goedde H. W. Metabolism of cyclophosphamide by aldehyde dehydrogenases. Adv. Exp. Med. Biol. 1995; 372: 115–122, [PUBMED], [INFOTRIEVE], [CSA]
- Airley R., Loncaster J., Davidson S., Bromley M., Roberts S., Patterson A., Hunter R., _Stratford I., West C. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin. C_ancer Res. 2001; 7: 928–934, [CSA]
- Alberts D. S., Mason-Liddil N., Plezia P. M., Roe D. J., Dorr R. T., Struck R. F., Phillips J. G. Lack of ranitidine effects on cyclophosphamide bone marrow toxicity or metabolism: a placebo-controlled clinical trial. J. Natl. Cancer Inst. 1991; 83: 1739–1742, [PUBMED], [INFOTRIEVE], [CSA]
- Aleksa K., Halachmi N., Ito S., Koren G. Renal ontogeny of ifosfamide nephrotoxicity. J. Lab. Clin. Med. 2004a; 144: 285–293, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Aleksa K., Halachmi N., Ito S., Koren G. A tubule cell model for ifosfamide nephrotoxicity. Can. J. Physiol. Pharmacol. 2005a; 83: 499–508, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Aleksa K., Ito S., Koren G. Renal-tubule metabolism of ifosfamide to the nephrotoxic chloroacetaldehyde: pharmacokinetic modeling for estimation of intracellular levels. J. Lab. Clin. Med. 2004b; 143: 159–162, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Aleksa K., Matsell D., Krausz K., Gelboin H., Ito S., Koren G. Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity. Pediatr. Nephrol. 2005b; 20, [CROSSREF], [CSA]
- Aleksa K., Woodland C., Koren G. Young age and the risk for ifosfamide-induced nephrotoxicity: a critical review of two opposing studies. Pediatr. Nephrol. 2001; 16: 1153–1158, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Allen J. D., Schinkel A. H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther. 2002; 1: 427–434, [PUBMED], [INFOTRIEVE], [CSA]
- Allen L. M., Creaven P. J. Pharmacokinetics of ifosfamide. Clin. Pharmacol. Ther. 1975; 17: 492–498, [PUBMED], [INFOTRIEVE], [CSA]
- Allen L. M., Creaven P. J., Nelson R. L. Studies on the human pharmacokinetics of isophosphamide (NSC-109724). Cancer Treat. Rep. 1976; 60: 451–458, [PUBMED], [INFOTRIEVE], [CSA]
- Ambudkar S. V., Dey S., Hrycyna C. A., Ramachandra M., Pastan I., Gottesman M. M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 1999; 39: 361–398, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Anderson L. W., Chen T. L., Colvin O. M., Grochow L. B., Collins J. M., Kennedy M. J., Strong J. M. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin. Cancer. Res. 1996; 2: 1481–1487, [PUBMED], [INFOTRIEVE], [CSA]
- Andersson B. S., Mroue M., Britten R. A., Farquhar D., Murray D. Mechanisms of cyclophosphamide resistance in a human myeloid leukemia cell line. Acta Oncol 1995; 34: 247–251, [PUBMED], [INFOTRIEVE], [CSA]
- Andersson B. S., Mroue M., Britten R. A., Murray D. The role of DNA damage in the resistance of human chronic myeloid leukemia cells to cyclophosphamide analogues. Cancer Res 1994a; 54: 5394–5400, [PUBMED], [INFOTRIEVE], [CSA]
- Andersson B. S., Murray D. Model studies of cyclophosphamide resistance in human myeloid leukemia. Cancer Treat. Res. 2002; 112: 211–235, [PUBMED], [INFOTRIEVE], [CSA]
- Andersson B. S., Sadeghi T., Siciliano M. J., Legerski R., Murray D. Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs. Cancer Chemother. Pharmacol. 1996; 38: 406–416, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Andersson P. O., Braide I., Nilsson-Ehle H. Trofosfamide as salvage therapy for anaplastic large cell lymphoma relapsing after high-dose chemotherapy. Leuk. Lymphoma. 2002; 43: 2351–2353, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Andersson T., Miners J. O., Veronese M. E., Birkett D. J. Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br. J. Clin. Pharmacol. 1994b; 37: 597–604, [PUBMED], [INFOTRIEVE], [CSA]
- Arcangeli G., Zaniboni A., Milano S., Meriggi F., Simoncini E., Marpicati P., Marini G. MICE: a new active combination for non-small cell lung cancer. Eur. J. Cancer. 1993; 29A: 1848–1850, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ariyoshi N., Miyazaki M., Toide K., Sawamura Y., Kamataki T. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem. Biophys. Res. Commun. 2001; 281: 1256–1260, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Arland M., Leuner S., Lange S., Bartsch R., Kahl C., Florschutz A., Franke A., Hoffkes H. G. Ifosamide, epirubicin and granulocyte colony-stimulating factor: a regimen for successful mobilization of peripheral blood progenitor cells in patients with multiple myeloma. Hematol. Oncol. 2001; 19: 59–66, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Arora V. Antisense strategies for redirection of drug metabolism: using Paclitaxel as a model. Methods Mol. Med. 2004; 106: 273–292, [CSA]
- Assaraf Y. G., Rothem L., Hooijberg J. H., Stark M., Ifergan I., Kathmann I., Dijkmans B. A., Peters G. J., Jansen G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem. 2003; 278: 6680–6686, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- ASTA Medica. (1999) Glufosfamide [investigator’s brochure]: Frankfurt, Germany.
- Au W., Sokova O. I., Kopnin B., Arrighi F. E. Cytogenetic toxicity of cyclophosphamide and its metabolites in vitro. Cytogenet. Cell. Genet. 1980; 26: 108–116, [PUBMED], [INFOTRIEVE], [CSA]
- Ayash L. J., Wright J. E., Tretyakov O., Gonin R., Elias A., Wheeler C., Eder J. P., Rosowsky A., Antman K., Frei E., 3rd. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J. Clin. Oncol. 1992; 10: 995–1000, [PUBMED], [INFOTRIEVE], [CSA]
- Bakir A. A., Levy P. S., Dunea G. The prognosis of lupus nephritis in African-Americans: a retrospective analysis. Am. J. Kidney Dis. 1994; 24: 159–171, [PUBMED], [INFOTRIEVE], [CSA]
- Balis F. M. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin. Pharmacokinet. 1986; 11: 223–235, [PUBMED], [INFOTRIEVE], [CSA]
- Barile-Fabris L., Ariza-Andraca R., Olguin-Ortega L., Jara L. J., Fraga-Mouret A., Miranda-Limon J. M., Fuentes de la Mata J., Clark P., Vargas F., Alocer-Varela J. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann. Rheum. Dis. 2005; 64: 620–625, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Baumann F., Preiss R. Cyclophosphamide and related anticancer drugs. J. Chromatogr. B. Biomed. Sci. Appl. 2001; 764: 173–192, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Becker R., Ritter A., Eichhorn U., Lips J., Bertram B., Wiessler M., Zdzienicka M. Z., Kaina B. Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug beta-D-glucosyl-ifosfamide mustard. Br. J. Cancer. 2002; 86: 130–135, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Beimler J. H., Andrassy K. Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?. Pediatr. Nephrol. 2004; 19: 949–955, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Benouchan M., Colombo B. M. Anti-angiogenic strategies for cancer therapy (Review). Int. J. Oncol. 2005; 27: 563–571, [PUBMED], [INFOTRIEVE], [CSA]
- Berrak S. G., Pearson M., Berberoglu S., Ilhan I. E., Jaffe N. High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr. Blood Cancer. 2005; 44: 215–219, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bertolini F., Paul S., Mancuso P., Monestiroli S., Gobbi A., Shaked Y., Kerbel R. S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 4342–4346, [PUBMED], [INFOTRIEVE], [CSA]
- Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., Knolle P. A., Thomas R. K., von Bergwelt-Baildon M., Debey S., Hallek M., Schultze J. L. Reduced frequencies and suppressive function of CD4+ CD25high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106, [CROSSREF], [CSA]
- Bhatia U., Danishefsky K., Traganos F., Darzynkiewicz Z. Induction of apoptosis and cell cycle-specific change in expression of p53 in normal lymphocytes and MOLT-4 leukemic cells by nitrogen mustard. Clin. Cancer. Res. 1995; 1: 873–880, [PUBMED], [INFOTRIEVE], [CSA]
- Biagi J. J., Herbert K. E., Smith C., Abdi E., Leahy M., Falkson C., Wolf M., Januszewicz H., Seymour J. F., Richards K., Matthews J. P., Dale B., Prince H. M. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leuk. Lymphoma. 2005; 46: 197–206, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Blaney S. M., Balis F. M., Berg S., Arndt C. A., Heideman R., Geyer J. R., Packer R., Adamson P. C., Jaeckle K., Klenke R., Aikin A., Murphy R., McCully C., Poplack D. G. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J. Clin. Oncol. 2005a; 23: 1555–1563, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Blaney S. M., Boyett J., Friedman H., Gajjar A., Geyer R., Horowtiz M., Hunt D., Kieran M., Kun L., Packer R., Phillips P., Pollack I. F., Prados M., Heideman R. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J. Clin. Oncol. 2005b; 23: 525–531, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Boal J. H., Williamson M., Boyd V. L., Ludeman S. M., Egan W. 31P NMR studies of the kinetics of bisalkylation by isophosphoramide mustard: comparisons with phosphoramide mustard. J. Med. Chem. 1989; 32: 1768–1773, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bocci G., Nicolaou K. C., Kerbel R. S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62: 6938–6943, [PUBMED], [INFOTRIEVE], [CSA]
- Bocci G., Tuccori M., Emmenegger U., Liguori V., Falcone A., Kerbel R. S., Del Tacca M. Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann. Oncol. 2005; 16: 1243–1252, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Boddy A. V., Cole M., Pearson A. D., Idle J. R. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother. Pharmacol. 1995a; 36: 53–60, [PUBMED], [INFOTRIEVE], [CSA]
- Boddy A. V., English M., Pearson A. D., Idle J. R., Skinner R. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur. J. Cancer. 1996a; 32A: 1179–1184, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Boddy A. V., Furtun Y., Sardas S., Sardas O., Idle J. R. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide. J. Natl. Cancer Inst. 1992; 84: 1744–1748, [PUBMED], [INFOTRIEVE], [CSA]
- Boddy A. V., Proctor M., Simmonds D., Lind M. J., Idle J. R. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients. Eur. J. Cancer. 1995b; 31A: 69–76, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Boddy A. V., Yule S. M. Metabolism and pharmacokinetics of oxazaphosphorines. Clin. Pharmacokinet. 2000; 38: 291–304, [PUBMED], [INFOTRIEVE], [CSA]
- Boddy A. V., Yule S. M., Wyllie R., Price L., Pearson A. D., Idle J. R. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res 1993; 53: 3758–3764, [PUBMED], [INFOTRIEVE], [CSA]
- Boddy A. V., Yule S. M., Wyllie R., Price L., Pearson A. D., Idle J. R. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration. Cancer Chemother. Pharmacol. 1996b; 38: 147–154, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bode U., Seif S. M., Levine A. S. Studies on the antidiuretic effect of cyclophosphamide: vasopressin release and sodium excretion. Med. Pediatr. Oncol. 1980; 8: 295–303, [PUBMED], [INFOTRIEVE], [CSA]
- Bonadonna G., Valagussa P., Moliterni A., Zambetti M., Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N. Engl. J. Med. 1995; 332: 901–906, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Boos J., Kupker F., Blaschke G., Jurgens H. Trofosfamide metabolism in different species–ifosfamide is the predominant metabolite. Cancer Chemother. Pharmacol. 1993; 33: 71–76, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Boos J., Welslau U., Ritter J., Blaschke G., Schellong G. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children. Cancer Chemother. Pharmacol. 1991; 28: 455–460, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Borner K., Kisro J., Bruggemann S. K., Hagenah W., Peters S. O., Wagner T. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Drug Metab. Dispos. 2000; 28: 573–576, [PUBMED], [INFOTRIEVE], [CSA]
- Borst P., Elferink R. O. Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 2002; 71: 537–592, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Borst P., Evers R., Kool M., Wijnholds J. The multidrug resistance protein family. Biochim. Biophys. Acta. 1999; 1461: 347–357, [PUBMED], [INFOTRIEVE], [CSA]
- Bosanquet A. G., Sturm I., Wieder T., Essmann F., Bosanquet M. I., Head D. J., Dorken B., Daniel P. T. Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1035–1044, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bourgeois H., Billiart I., Chabrun V., Chieze S., Lemerre D., Germain T., Ferrand V., Meurice J. C., Daban A., Tourani J. M. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma. Am. J. Clin. Oncol. 2004; 27: 89–95, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brade W. P., Herdrich K., Varini M. Ifosfamide – pharmacology, safety and therapeutic potential. Cancer Treat. Rev. 1985; 12: 1–47, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brain E. G., Yu L. J., Gustafsson K., Drewes P., Waxman D. J. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. Br. J. Cancer. 1998; 77: 1768–1776, [PUBMED], [INFOTRIEVE], [CSA]
- Bramwell V., Calvert R. T., Edwards G., Scarffe H., Crowther D. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother. Pharmacol. 1979; 3: 253–259, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bramwell V. H., Mouridsen H. T., Santoro A., Blackledge G., Somers R., Verweij J., Dombernowsky P., Onsrud M., Thomas D., Sylvester R. Cyclophosphamide versus ifosfamide: a randomized phase II trial in adult soft-tissue sarcomas. The European Organization for Research and Treatment of Cancer [EORTC], Soft Tissue and Bone Sarcoma Group. Cancer Chemother. Pharmacol. 1993; 31(Suppl 2)S180–184, [PUBMED], [INFOTRIEVE], [CSA]
- Bramwell V. H., Mouridsen H. T., Santoro A., Blackledge G., Somers R., Verwey J., Dombernowsky P., Onsrud M., Thomas D., Sylvester R. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur. J. Cancer Clin. Oncol. 1987; 23: 311–321, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Braybrooke J. P., Slade A., Deplanque G., Harrop R., Madhusudan S., Forster M. D., Gibson R., Makris A., Talbot D. C., Steiner J., White L., Kan O., Naylor S., Carroll M. W., Kingsman S. M., Harris A. L. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin. Cancer Res. 2005; 11: 1512–1520, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Briasoulis E., Judson I., Pavlidis N., Beale P., Wanders J., Groot Y., Veerman G., Schuessler M., Niebch G., Siamopoulos K., Tzamakou E., Rammou D., Wolf L., Walker R., Hanauske A. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J. Clin. Oncol. 2000; 18: 3535–3544, [PUBMED], [INFOTRIEVE], [CSA]
- Briasoulis E., Pavlidis N., Terret C., Bauer J., Fiedler W., Schoffski P., Raoul J. L., Hess D., Selvais R., Lacombe D., Bachmann P., Fumoleau P. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. Eur. J. Cancer. 2003; 39: 2334–2340, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Brinker A., Kisro J., Letsch C., Bruggemann S. K., Wagner T. New insights into the clinical pharmacokinetics of trofosfamide. Int. J. Clin. Pharmacol. Ther. 2002; 40: 376–381, [PUBMED], [INFOTRIEVE], [CSA]
- Brock N., Hilgard P., Peukert M., Pohl J., Sindermann H. Basis and new developments in the field of oxazaphosphorines. Cancer Invest 1988; 6: 513–532, [PUBMED], [INFOTRIEVE], [CSA]
- Brock N., Pohl J. Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics. IARC Sci Publ 1986; 78: 269–279, [PUBMED], [INFOTRIEVE], [CSA]
- Brock N., Stekar J., Pohl J., Niemeyer U., Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung 1979; 29: 659–661, [PUBMED], [INFOTRIEVE], [CSA]
- Brodsky R. A. High-dose cyclophosphamide for aplastic anemia and autoimmunity. Curr. Opin. Oncol. 2002; 14: 143–146, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bruggemann S. K., Kisro J., Wagner T. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide. Cancer Res 1997; 57: 2676–2680, [PUBMED], [INFOTRIEVE], [CSA]
- Buchler M., Konig J., Brom M., Kartenbeck J., Spring H., Horie T., Keppler D. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMRP, reveals a novel conjugate export pump deficient in hyperbilirubinemic rats. J. Biol. Chem. 1996; 271: 15091–15098, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Buda A., Dell’Anna T., Signorelli M., Mangioni C. Role of ifosfamide in cervical cancer: an overview. Oncology 2003; 65(Suppl 2)63–66, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Buda A., Fossati R., Colombo N., Fei F., Floriani I., Gueli Alletti D., Katsaros D., Landoni F., Lissoni A., Malzoni C., Sartori E., Scollo P., Torri V., Zola P., Mangioni C. Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. J. Clin. Oncol. 2005; 23: 4137–4145, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bunting K. D., Lindahl R., Townsend A. J. Oxazaphosphorine-specific resistance in human MCF-7 breast carcinoma cell lines expressing transfected rat class 3 aldehyde dehydrogenase. J. Biol. Chem. 1994; 269: 23197–23203, [PUBMED], [INFOTRIEVE], [CSA]
- Bunting K. D., Townsend A. J. De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality. J. Biol. Chem. 1996a; 271: 11884–11890, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bunting K. D., Townsend A. J. Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme. J. Biol. Chem. 1996b; 271: 11891–11896, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bunting K. D., Townsend A. J. Dependence of aldehyde dehydrogenase-mediated oxazaphosphorine resistance on soluble thiols: importance of thiol interactions with the secondary metabolite acrolein. Biochem. Pharmacol. 1998; 56: 31–39, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Burgaz S., Karahalil B., Bayrak P., Taskin L., Yavuzaslan F., Bokesoy I., Anzion R. B., Bos R. P., Platin N. Urinary cyclophosphamide excretion and micronuclei frequencies in peripheral lymphocytes and in exfoliated buccal epithelial cells of nurses handling antineoplastics. Mutat. Res. 1999; 439: 97–104, [PUBMED], [INFOTRIEVE], [CSA]
- Burger H., Foekens J. A., Look M. P., Meijer-van Gelder M. E., Klijn J. G., Wiemer E. A., Stoter G., Nooter K. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response. Clin. Cancer Res. 2003; 9: 827–836, [PUBMED], [INFOTRIEVE], [CSA]
- Busse D., Busch F. W., Bohnenstengel F., Eichelbaum M., Fischer P., Opalinska J., Schumacher K., Schweizer E., Kroemer H. K. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J. Clin. Oncol. 1997; 15: 1885–1896, [PUBMED], [INFOTRIEVE], [CSA]
- Busse D., Busch F. W., Schweizer E., Bohnenstengel F., Eichelbaum M., Fischer P., Schumacher K., Aulitzky W. E., Kroemer H. K. Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism. Cancer Chemother. Pharmacol. 1999; 43: 263–268, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Busse D., Kroemer H. K. Dose-dependency of oxazaphosphorine pharmacokinetics. Int. J. Clin. Pharmacol. Ther. 1997; 35: 71–72, [PUBMED], [INFOTRIEVE], [CSA]
- Busse D., Wurthwein G., Hinske C., Hempel G., Fromm M. F., Eichelbaum M., Kroemer H. K., Busch F. W. Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration. Naunyn Schmiedebergs Arch Pharmacol 2002; 366: 218–225, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Byfield J. E., Calabro-Jones P. M. Carrier-dependent and carrier-independent transport of anti-cancer alkylating agents. Nature 1981; 294: 281–283, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cai Y., Wu M. H., Xu-Welliver M., Pegg A. E., Ludeman S. M., Dolan M. E. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res 2000; 60: 5464–5469, [PUBMED], [INFOTRIEVE], [CSA]
- Calabro F., Sternberg C. N. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J. Urol. 2002; 20: 158–166, [PUBMED], [INFOTRIEVE], [CSA]
- Cantuaria G., Fagotti A., Ferrandina G., Magalhaes A., Nadji M., Angioli R., Penalver M., Mancuso S., Scambia G. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 2001; 92: 1144–1150, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Carlson L., Goren M. P., Bush D. A., Griener J. C., Quigley R., Tkaczewski I., Kamen B. A., Weitman S. D. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms’ tumor. Cancer Chemother. Pharmacol. 1998; 41: 140–146, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cates L. A., Jones G. S., Jr., Good D. J., Tsai H. Y., Li V. S., Caron N., Tu S. C., Kimball A. P. Cyclophosphamide potentiation and aldehyde oxidase inhibition by phosphorylated aldehydes and acetals. J. Med. Chem. 1980; 23: 300–304, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cayre A., Penault-Llorca F., De Latour M., Rolhion C., Feillel V., Ferriere J. P., Kwiatkowski F., Finat-Duclos F., Verrelle P. O(6)-methylguanine-DNA methyl transferase gene expression and prognosis in breast carcinoma. Int. J. Oncol. 2002; 21: 1125–1131, [PUBMED], [INFOTRIEVE], [CSA]
- Cerny T., Leyvraz S., von Briel T., Kupfer A., Schaad R., Schmitz S. F., Honegger P., Sessa C., Brunner J., Boddy A. V. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: a pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol. 1999; 10: 1087–1094, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cerny T., Margison J. M., Thatcher N., Wilkinson P. M. Bioavailability of ifosfamide in patients with bronchial carcinoma. Cancer Chemother. Pharmacol. 1986; 18: 261–264, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chang T. K., Weber G. F., Crespi C. L., Waxman D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993; 53: 5629–5637, [PUBMED], [INFOTRIEVE], [CSA]
- Chang T. K., Yu L., Goldstein J. A., Waxman D. J. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997a; 7: 211–221, [PUBMED], [INFOTRIEVE], [CSA]
- Chang T. K., Yu L., Maurel P., Waxman D. J. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res 1997b; 57: 1946–1954, [PUBMED], [INFOTRIEVE], [CSA]
- Chen C.-J., Chin J. E., Ueda K., Clark D. P., Pastan I., Gottesman M. M., Roninson I. B. Internal duplication and homology with bacterial transport proteins in mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1996a; 47: 381–389, [CSA]
- Chen C. S., Jounaidi Y., Waxman D. J. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab. Dispos. 2005, in press[CSA]
- Chen C. S., Lin J. T., Goss K. A., He Y. A., Halpert J. R., Waxman D. J. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol. Pharmacol. 2004; 65: 1278–1285, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chen G., Teicher B. A., Frei E., 3rd. Biochemical characterization of in vivo alkylating agent resistance of a murine EMT-6 mammary carcinoma. Implication for systemic involvement in the resistance phenotype. Cancer Biochem. Biophys. 1998; 16: 139–155, [PUBMED], [INFOTRIEVE], [CSA]
- Chen G., Waxman D. J. Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochem. Pharmacol. 1995a; 49: 1691–1701, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chen L., Waxman D. J. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 1995b; 55: 581–589, [PUBMED], [INFOTRIEVE], [CSA]
- Chen L., Waxman D. J. Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr. Pharm. Des. 2002; 8: 1405–1416, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chen L., Waxman D. J., Chen D., Kufe D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. Cancer Res 1996b; 56: 1331–1340, [PUBMED], [INFOTRIEVE], [CSA]
- Chen T. L., Passos-Coelho J. L., Noe D. A., Kennedy M. J., Black K. C., Colvin O. M., Grochow L. B. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995; 55: 810–816, [PUBMED], [INFOTRIEVE], [CSA]
- Chen Z. P., Remack J., Brent T. P., Mohr G., Panasci L. C. Extraneuronal monoamine transporter expression and DNA repair vis-a-vis 2-chloroethyl-3-sarcosinamide-1-nitrosourea cytotoxicity in human tumor cell lines. Clin. Cancer Res. 1999a; 5: 4186–4190, [PUBMED], [INFOTRIEVE], [CSA]
- Chen Z. P., Wang G., Huang Q., Sun Z. F., Zhou L. Y., Wang A. D., Panasci L. C. Enhanced antitumor activity of sarCNU in comparison to BCNU in an extraneuronal monoamine transporter positive human glioma xenograft model. J. Neurooncol. 1999b; 44: 7–14, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chen Z. P., Wang Z. M., Carter C. A., Alley M. C., Mohr G., Panasci L. C. Both extraneuronal monoamine transporter and O(6)-methylguanine-DNA methyltransferase expression influence the antitumor efficacy of 2-chloroethyl-3-sarcosinamide- 1-nitrosourea in human tumor xenografts. J. Pharmacol. Exp. Ther. 2001; 296: 712–715, [PUBMED], [INFOTRIEVE], [CSA]
- Chien M. M., Ashman R. F. The effects of nitrogen mustards on the proliferative and Ig synthetic response of human peripheral blood lymphocytes. Immunopharmacology 1986; 12: 155–166, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Chrystal K., Cheong K., Harper P. Chemotherapy of small cell lung cancer: state of the art. Curr. Opin. Oncol. 2004; 16: 136–140, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Citron M. L. Dose density in adjuvant chemotherapy for breast cancer. Cancer Invest 2004; 22: 555–568, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Clavel B., Mathe G., Hayat M. [Phase II therapeutic trial (screening) of ifosfamide in hematosarcomas and solid tumors]. Sem. Hop. Ther. 1975; 51: 7–10, [PUBMED], [INFOTRIEVE], [CSA]
- Code E. L., Crespi C. L., Penman B. W., Gonzalez F. J., Chang T. K., Waxman D. J. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 1997; 25: 985–993, [PUBMED], [INFOTRIEVE], [CSA]
- Codegoni A. M., Broggini M., Pitelli M. R., Pantarotto M., Torri V., Mangioni C., D’Incalci M. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol. Oncol. 1997; 65: 130–137, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cohen M. H., Creaven P. J., Tejada F., Hansen H. H., Muggia F., Mittelman A., Selawry O. S. Phase I clinical trial of isophosphamide (NSC-109724). Cancer Chemother. Rep. 1975; 59: 751–755, [PUBMED], [INFOTRIEVE], [CSA]
- Colleoni M., Litman H. J., Castiglione-Gertsch M., Sauerbrei W., Gelber R. D., Bonetti M., Coates A. S., Schumacher M., Bastert G., Rudenstam C. M., Schmoor C., Lindtner J., Collins J., Thurlimann B., Holmberg S. B., Crivellari D., Beyerle C., Neumann R. L., Goldhirsch A. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF. Br. J. Cancer. 2002; 86: 1705–1714, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Colvin M. The comparative pharmacology of cyclophosphamide and ifosfamide. Semin. Oncol. 1982; 9: 2–7, [PUBMED], [INFOTRIEVE], [CSA]
- Colvin M., Brundrett R. B., Kan M. N., Jardine I., Fenselau C. Alkylating properties of phosphoramide mustard. Cancer Res 1976; 36: 1121–1126, [PUBMED], [INFOTRIEVE], [CSA]
- Colvin M., Russo J. E., Hilton J., Dulik D. M., Fenselau C. Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues. Adv. Enzyme Regul. 1988; 27: 211–221, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Colvin O. M. An overview of cyclophosphamide development and clinical applications. Curr. Pharm. Des. 1999; 5: 555–560, [PUBMED], [INFOTRIEVE], [CSA]
- Comandone A., Leone L., Oliva C., Frustaci S., Monteleone M., Colussi A. M., Dal Canton O., Bergnolo P., Boglione A., Bumma C. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. J. Chemother. 1998; 10: 385–393, [PUBMED], [INFOTRIEVE], [CSA]
- Conrad S., Kauffmann H. M., Ito K., Deeley R. G., Cole S. P., Schrenk D. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J. Hum. Genet. 2001; 46: 656–663, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Conrad S., Kauffmann H. M., Ito K., Leslie E. M., Deeley R. G., Schrenk D., Cole S. P. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 2002; 12: 321–330, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Coombes R. C., Howell A., Emson M., Peckitt C., Gallagher C., Bengala C., Tres A., Welch R., Lawton P., Rubens R., Woods E., Haviland J., Vigushin D., Kanfer E., Bliss J. M. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann. Oncol. 2005; 16: 726–734, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Cooper R., Sarioglu S., Sokmen S., Fuzun M., Kupelioglu A., Valentine H., Gorken I. B., Airley R., West C. Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma?. Br. J. Cancer. 2003; 89: 870–876, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Corlett S. A., Parker D., Chrystyn H. Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma. Br. J. Clin. Pharmacol. 1995; 39: 452–455, [PUBMED], [INFOTRIEVE], [CSA]
- Cox P. J., Phillips B. J., Thomas P. Studies on the selective action of cyclophosphamide (NSC-26271): Inactivation of the hydroxylated metabolite by tissue-soluble enzymes. Cancer Treat. Rep. 1976; 60: 321–326, [PUBMED], [INFOTRIEVE], [CSA]
- Crabb D. W., Matsumoto M., Chang D., You M. Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc. Nutr. Soc. 2004; 63: 49–63, [PUBMED], [INFOTRIEVE], [CSA]
- Crews K. R., Stewart C. F., Liu T., Rodriguez-Galindo C., Santana V. M., Daw N. C. Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. J. Pediatr. Hematol. Oncol. 2004; 26: 764–776, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Crook T. R., Souhami R. L., McLean A. E. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res 1986a; 46: 5029–5034, [PUBMED], [INFOTRIEVE], [CSA]
- Crook T. R., Souhami R. L., Whyman G. D., McLean A. E. Glutathione depletion as a determinant of sensitivity of human leukemia cells to cyclophosphamide. Cancer Res 1986b; 46: 5035–5038, [PUBMED], [INFOTRIEVE], [CSA]
- Curtin J. P., Koonings P. P., Gutierrez M., Schlaerth J. B., Morrow C. P. Ifosfamide-induced neurotoxicity. Gynecol. Oncol. 1991; 42: 193–196, discussion 191–192[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Czownicki Z., Utracka B., Till A., Styrna M. [Clinical evaluation of ifosfamide in the treatment of malignant neoplasms]. Nowotwory 1973; 23: 285–290, [PUBMED], [INFOTRIEVE], [CSA]
- Dachs G. U., Tupper J., Tozer G. M. From bench to bedside for gene-directed enzyme prodrug therapy of cancer. Anticancer Drugs 2005; 16: 349–359, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Damia G., Guidi G., D’Incalci M. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. Eur. J. Cancer. 1998; 34: 1783–1788, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- David K. A., Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am. J. Clin. Oncol. 2005; 28: 277–280, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- De Bruijn E. A., Slee P. H., Van Oosterom A. T., Lameijer D. W., Roozendaal K. J., Tjaden U. R. Pharmacokinetics of intravenous and oral cyclophosphamide in the presence of methotrexate and fluorouracil. Pharm. Weekbl. Sci. 1988; 10: 200–206, [PUBMED], [INFOTRIEVE], [CSA]
- de Groot C. J., Martens A. C., Hagenbeek A. Aldehyde dehydrogenase involvement in a variant of the brown Norway rat acute myelocytic leukaemia (BNML) that acquired cyclophosphamide resistance in vivo. Eur. J. Cancer. 1994; 30A: 2137–2143, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- de Jonge M. E., Huitema A. D., Holtkamp M. J., van Dam S. M., Beijnen J. H., Rodenhuis S. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother. Pharmacol 2005a; 56, [CROSSREF], [CSA]
- de Jonge M. E., Huitema A. D., Schellens J. H., Rodenhuis S., Beijnen J. H. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin. Pharmacokinet. 2005b; 44: 147–173, [PUBMED], [INFOTRIEVE], [CSA]
- DeAngelis L. M., Boutros D. Leptomeningeal metastasis. Cancer Invest 2005; 23: 145–154, [PUBMED], [INFOTRIEVE], [CSA]
- DeLeve L. D. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830–837, [PUBMED], [INFOTRIEVE], [CSA]
- DeMario M. D., Ratain M. J. Oral chemotherapy – rationale and future directions. J. Clin. Oncol. 1998; 16: 2557–2567, [PUBMED], [INFOTRIEVE], [CSA]
- Demirer T., Buckner C. D., Appelbaum F. R., Bensinger W. I., Sanders J., Lambert K., Clift R., Fefer A., Storb R., Slattery J. T. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996a; 17: 491–495, [PUBMED], [INFOTRIEVE], [CSA]
- Demirer T., Buckner C. D., Appelbaum F. R., Lambert K., Bensinger W. I., Clift R., Storb R., Slattery J. T. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996b; 17: 341–346, [PUBMED], [INFOTRIEVE], [CSA]
- Denny W. A. Tumor-activated prodrugs–a new approach to cancer therapy. Cancer Invest 2004; 22: 604–619, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Desta Z., Zhao X., Shin J. G., Flockhart D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 2002; 41: 913–958, [PUBMED], [INFOTRIEVE], [CSA]
- Diah S. K., Smitherman P. K., Aldridge J., Volk E. L., Schneider E., Townsend A. J., Morrow C. S. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res 2001; 61: 5461–5467, [PUBMED], [INFOTRIEVE], [CSA]
- Dillman R. O., Barth N. M., VanderMolen L. A., Allen K., Beutel L. D., Chico S. High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants. Am. J. Clin. Oncol. 2005; 28: 281–288, [PUBMED], [INFOTRIEVE], [CSA]
- DiMaggio J. R., Brown R., Baile W. F., Schapira D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer 1994; 73: 1509–1514, [PUBMED], [INFOTRIEVE], [CSA]
- Dimopoulos M. A., Hamilos G., Zomas A., Gika D., Efstathiou E., Grigoraki V., Poziopoulos C., Xilouri I., Zorzou M. P., Anagnostopoulos N., Anagnostopoulos A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol. J. 2004; 5: 112–117, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- D’Incalci M., Facchinetti T., Bolis G., Mangioni C., Morasca L. Pharmacokinetics of cyclophosphamide after prolonged low dose treatment in ovarian cancer patients. Eur. J. Drug Metab. Pharmacokinet. 1979; 4: 83–85, [CSA]
- Dirven H. A., Megens L., Oudshoorn M. J., Dingemanse M. A., van Ommen B., van Bladeren P. J. Glutathione conjugation of the cytostatic drug ifosfamide and the role of human glutathione S-transferases. Chem. Res. Toxicol. 1995; 8: 979–986, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dirven H. A., van Ommen B., van Bladeren P. J. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione. Cancer Res 1994a; 54: 6215–6220, [PUBMED], [INFOTRIEVE], [CSA]
- Dirven H. A., Venekamp J. C., van Ommen B., van Bladeren P. J. The interaction of glutathione with 4-hydroxycyclophosphamide and phosphoramide mustard, studied by 31P nuclear magnetic resonance spectroscopy. Chem. Biol. Interact. 1994b; 93: 185–196, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dockham P. A., Sreerama L., Sladek N. E. Relative contribution of human erythrocyte aldehyde dehydrogenase to the systemic detoxification of the oxazaphosphorines. Drug Metab. Dispos. 1997; 25: 1436–1441, [PUBMED], [INFOTRIEVE], [CSA]
- Dole M. G., Jasty R., Cooper M. J., Thompson C. B., Nunez G., Castle V. P. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55: 2576–2582, [PUBMED], [INFOTRIEVE], [CSA]
- Dollner R., Dietz A., Kopun M., Helbig M., Wallner F., Granzow C. Ex vivo responsiveness of head and neck squamous cell carcinoma to glufosfamide, a novel alkylating agent. Anticancer Res 2004; 24: 2947–2951, [PUBMED], [INFOTRIEVE], [CSA]
- Domen J., Weissman I. L. Hematopoietic stem cells and other hematopoietic cells show broad resistance to chemotherapeutic agents in vivo when overexpressing bcl-2. Exp. Hematol. 2003; 31: 631–639, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Domeyer B. E., Sladek N. E. Metabolism of 4-hydroxycyclophosphamide/aldophosphamide in vitro. Biochem. Pharmacol. 1980; 29: 2903–2912, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Donato M. L., Aleman A., Champlin R. E., Saliba R. M., Wharton J. T., Burke T. W., Bodurka D. C., Bevers M. W., Levenback C. F., Wolf J. K., Bast R. C., Freedman R. S., Ippoliti C., Brewer M., Gajewski J. L., Gershenson D. M. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 2004; 33: 1219–1224, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Donfrancesco A., Jenkner A., Castellano A., Ilari I., Milano G. M., De Sio L., Cozza R., Fidani P., Deb G., De Laurentis C., Inserra A., Dominici C. Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age. Acta Paediatr. Suppl. 2004; 93: 6–11, [PUBMED], [INFOTRIEVE], [CSA]
- Dong Q., Bullock N., Ali-Osman F., Colvin O. M., Bigner D. D., Friedman H. S. Repair analysis of 4-hydroperoxycyclophosphamide-induced DNA interstrand crosslinking in the c‐myc gene in 4-hydroperoxycyclophosphamide-sensitive and -resistant medulloblastoma cell lines. Cancer Chemother. Pharmacol. 1996; 37: 242–246, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dooley J. S., James C. A., Rogers H. J., Stuart-Harris R. Biliary elimination of cyclophosphamide in man. Cancer Chemother Pharmacol 1982; 9: 26–29, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dooley M. A., Hogan S., Jennette C., Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188–1195, [PUBMED], [INFOTRIEVE], [CSA]
- Dotzlaw H., Leygue E., Watson P., Murphy L. C. The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin. Cancer Res. 1999; 5: 2103–2107, [PUBMED], [INFOTRIEVE], [CSA]
- Dubourg L., Michoudet C., Cochat P., Baverel G. Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. J. Am. Soc. Nephrol. 2001; 12: 1615–1623, [PUBMED], [INFOTRIEVE], [CSA]
- Ducharme M. P., Bernstein M. L., Granvil C. P., Gehrcke B., Wainer I. W. Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers. Cancer Chemother. Pharmacol. 1997; 40: 531–533, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dumez H., Reinhart W. H., Guetens G., de Bruijn E. A. Human red blood cells: rheological aspects, uptake, and release of cytotoxic drugs. Crit. Rev. Clin. Lab. Sci. 2004; 41: 159–188, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Edwards J. C., Leandro M. J., Cambridge G. B lymphocyte depletion in rheumatoid arthritis: targeting of CD20. Curr. Dir. Autoimmun. 2005; 8: 175–192, [PUBMED], [INFOTRIEVE], [CSA]
- Egorin M. J., Forrest A., Belani C. P., Ratain M. J., Abrams J. S., Van Echo D. A. A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 1989; 49: 3129–3133, [PUBMED], [INFOTRIEVE], [CSA]
- El Weshi A., Memon M., Raja M., Bazarbashi S., Rahal M., El Foudeh M., Pai C., Allam A., El Hassan I., Ezzat A. VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors. Am. J. Clin. Oncol. 2004; 27: 529–534, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Emmenegger U., Man S., Shaked Y., Francia G., Wong J. W., Hicklin D. J., Kerbel R. S. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004; 64: 3994–4000, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ensom M. H. H., Chang T. K. H., Patel P. Pharmacogenetics – the therapeutic drug monitoring of the future?. Clin. Pharmacokinet. 2001; 40: 783–802, [PUBMED], [INFOTRIEVE], [CSA]
- Erlichman C., Soldin S. J., Hardy R. W., Thiessen J. J., Sturgeon J. F., Fine S., Baskerville T. Disposition of cyclophosphamide on two consecutive cycles of treatment in patients with ovarian carcinoma. Arzneimittelforschung 1988; 38: 839–842, [PUBMED], [INFOTRIEVE], [CSA]
- Escalon M. P., Liu N. S., Yang Y., Hess M., Walker P. L., Smith T. L., Dang N. H. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer 2005; 103: 2091–2098, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Faber O. K., Mouridsen H. T., Skovsted L. The biotransformation of cyclophosphamide in man: influence of prednisone. Acta Pharmacol. Toxicol. (Copenh) 1974; 35: 195–200, [CSA]
- Fahrig R., Heinrich J. C., Nickel B., Wilfert F., Leisser C., Krupitza G., Praha C., Sonntag D., Fiedler B., Scherthan H., Ernst H. Inhibition of induced chemoresistance by cotreatment with (E)-5-(2-bromovinyl)-2’-deoxyuridine (RP101). Cancer Res 2003; 63: 5745–5753, [PUBMED], [INFOTRIEVE], [CSA]
- Fasola G., Lo Greco P., Calori E., Zilli M., Verlicchi F., Motta M. R., Ricci P., Baccarani M., Tura S. Pharmacokinetics of high-dose cyclophosphamide for bone marrow transplantation. Haematologica 1991; 76: 120–125, [PUBMED], [INFOTRIEVE], [CSA]
- Fenselau C., Kan M. N., Rao S. S., Myles A., Friedman O. M., Colvin M. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res 1977; 37: 2538–2543, [PUBMED], [INFOTRIEVE], [CSA]
- Ferme C., Bastion Y., Lepage E., Berger F., Brice P., Morel P., Gabarre J., Nedellec G., Reman O., Cheron N. The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin’s disease. Ann. Oncol. 1995; 6: 543–549, [PUBMED], [INFOTRIEVE], [CSA]
- Ferrari S., Pieretti F., Verri E., Tolentinis L., Cesari M., Versari M., Zolezzi C., Lamanna G., Bacci G. Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate. Anticancer Drugs 2005; 16: 733–738, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Filipits M., Pohl G., Rudas M., Dietze O., Lax S., Grill R., Pirker R., Zielinski C. C., Hausmaninger H., Kubista E., Samonigg H., Jakesz R. Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 2005; 23: 1161–1168, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fine D. M. Pharmacological therapy of lupus nephritis. JAMA 2005; 293: 3053–3060, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fleer R., Brendel M. Toxicity, interstrand cross-links and DNA fragmentation induced by ‘activated’ cyclophosphamide in yeast: comparative studies on 4-hydroperoxy-cyclophosphamide, its monofunctional analogon, acrolein, phosphoramide mustard, and nor-nitrogen mustard. Chem. Biol. Interact. 1982; 39: 1–15, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fleming R. A. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy 1997; 17: 146S–154S, [PUBMED], [INFOTRIEVE], [CSA]
- Frei E., 3rd, Cucchi C. A., Rosowsky A., Tantravahi R., Bernal S., Ervin T. J., Ruprecht R. M., Haseltine W. A. Alkylating agent resistance: in vitro studies with human cell lines. Proc. Natl. Acad. Sci. USA. 1985; 82: 2158–2162, [PUBMED], [INFOTRIEVE], [CSA]
- Frei E., 3rd, Holden S. A., Gonin R., Waxman D. J., Teicher B. A. Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemother. Pharmacol. 1993; 33: 113–122, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Frei E., 3rd, Teicher B. A., Holden S. A., Cathcart K. N., Wang Y. Y. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48: 6417–6423, [PUBMED], [INFOTRIEVE], [CSA]
- Fridrik M. A., Hausmaninger H., Linkesch W., Greil R., Krieger O., Baldinger C., Klocker J., Pont J., Oberaigner W. Long-term results of dose density therapy in patients with aggressive lymphoma. Ann. Hematol. 2005; 84: 217–222, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Friedman H. S., Colvin O. M., Kaufmann S. H., Ludeman S. M., Bullock N., Bigner D. D., Griffith O. W. Cyclophosphamide resistance in medulloblastoma. Cancer Res 1992; 52: 5373–5378, [PUBMED], [INFOTRIEVE], [CSA]
- Friedman H. S., Johnson S. P., Colvin O. M. Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines. Cancer Treat. Res. 2002; 112: 199–209, [PUBMED], [INFOTRIEVE], [CSA]
- Friedman H. S., Pegg A. E., Johnson S. P., Loktionova N. A., Dolan M. E., Modrich P., Moschel R. C., Struck R., Brent T. P., Ludeman S., Bullock N., Kilborn C., Keir S., Dong Q., Bigner D. D., Colvin O. M. Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase. Cancer Chemother. Pharmacol. 1999; 43: 80–85, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fukuen S., Fukuda T., Matsuda H., Sumida A., Yamamoto I., Inaba T., Azuma J. Identification of the novel splicing variants for the hPXR in human livers. Biochem. Biophys. Res. Commun. 2002; 298: 433–438, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Furlanut M., Franceschi L. Pharmacology of ifosfamide. Oncology 2003; 65(Suppl 2)2–6, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Galpin A. J., Evans W. E. Therapeutic drug monitoring in cancer management. Clin. Chem. 1993; 39: 2419–2430, [PUBMED], [INFOTRIEVE], [CSA]
- Gamcsik M. P., Dolan M. E., Andersson B. S., Murray D. Mechanisms of resistance to the toxicity of cyclophosphamide. Curr. Pharm. Des. 1999; 5: 587–605, [PUBMED], [INFOTRIEVE], [CSA]
- Gehi A., Webb A., Nolte M., Davis J., Jr. Treatment of systemic lupus erythematosus-associated type B insulin resistance syndrome with cyclophosphamide and mycophenolate mofetil. Arthritis Rheum 2003; 48: 1067–1070, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Germann N., Urien S., Rodgers A. H., Ratterree M., Struck R. F., Waud W. R., Serota D. G., Bastian G., Jursic B. S., Morgan L. R. Comparative preclinical toxicology and pharmacology of isophosphoramide mustard, the active metabolite of ifosfamide. Cancer Chemother. Pharmacol. 2005; 55: 143–151, [PUBMED], [INFOTRIEVE], [CSA]
- Gervot L., Rochat B., Gautier J. C., Bohnenstengel F., Kroemer H., de Berardinis V., Martin H., Beaune P., de Waziers I. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 1999; 9: 295–306, [PUBMED], [INFOTRIEVE], [CSA]
- Gheuens E., Slee P. H., de Bruijn E. A. Bioavailability of cyclophosphamide in the CMF regimen. Onkologie 1990; 13: 203–206, [PUBMED], [INFOTRIEVE], [CSA]
- Ghiringhelli F., Larmonier N., Schmitt E., Parcellier A., Cathelin D., Garrido C., Chauffert B., Solary E., Bonnotte B., Martin F. CD4 + CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 2004; 34: 336–344, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Giaccone G., Smit E. F., de Jonge M., Dansin E., Briasoulis E., Ardizzoni A., Douillard J. Y., Spaeth D., Lacombe D., Baron B., Bachmann P., Fumoleau P. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. Eur. J. Cancer. 2004; 40: 667–672, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Giai M., Biglia N., Sismondi P. Chemoresistance in breast tumors. Eur. J. Gynaecol. Oncol. 1991; 12: 359–373, [PUBMED], [INFOTRIEVE], [CSA]
- Gibson G. G., Plant N. J., Swales K. E., Ayrton A., El-Sankary W. Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica 2002; 32: 165–206, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gilard V., Martino R., Malet-Martino M., Niemeyer U. Stability of commercial formulations and aqueous solutions of ifosfamide: a reply. Drug Metab. Dispos. 1997; 25: 927–931, [PUBMED], [INFOTRIEVE], [CSA]
- Gilman A. The initial clinical trial of nitrogen mustard. Am. J. Surg. 1963; 105: 574–578, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ginzler E. M., Moldovan I. Systemic lupus erythematosus trials: successes and issues. Curr. Opin. Rheumatol. 2004; 16: 499–504, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Giorgianni F., Bridson P. K., Sorrentino B. P., Pohl J., Blakley R. L. Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3. Biochem. Pharmacol. 2000; 60: 325–338, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gladstone D. E., Prestrud A. A., Brannagan T. H., 3rd. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality of life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J. Peripher. Nerv. Syst. 2005; 10: 11–16, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Glode L. M., Barqawi A., Crighton F., Crawford E. D., Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003; 98: 1643–1648, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goldenberg G. J., Froese E. K. Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem. Pharmacol. 1985; 34: 763–770, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goldenberg G. J., Lam H. Y., Begleiter A. Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J. Biol. Chem. 1979; 254: 1057–1064, [PUBMED], [INFOTRIEVE], [CSA]
- Goldenberg G. J., Lee M., Lam H. Y., Begleiter A. Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro. Cancer Res 1977; 37: 755–760, [PUBMED], [INFOTRIEVE], [CSA]
- Goncalves A., Braud A. C., Viret F., Tarpin C., Charaffe-Jauffret E., Jacquemier J., Maraninchi D., Viens P. High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study. Anticancer Res 2005; 25: 663–667, [PUBMED], [INFOTRIEVE], [CSA]
- Gonzalez-Martin A., Crespo C., Garcia-Lopez J. L., Pedraza M., Garrido P., Lastra E., Moyano A. Ifosfamide and vinorelbine in advanced platinum-resistant ovarian cancer: excessive toxicity with a potentially active regimen. Gynecol. Oncol. 2002; 84: 368–73, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Goodwin B., Hodgson E., Liddle C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 1999; 56: 1329–1339, [PUBMED], [INFOTRIEVE], [CSA]
- Goodwin B., Moore L. B., Stoltz C. M., McKee D. D., Kliewer S. A. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 2001; 60: 427–431, [PUBMED], [INFOTRIEVE], [CSA]
- Goren M. P. Oral administration of mesna with ifosfamide. Semin. Oncol. 1996; 23: 91–96, [PUBMED], [INFOTRIEVE], [CSA]
- Goren M. P., Wright R. K., Pratt C. B., Pell F. E. Dechloroethylation of ifosfamide and neurotoxicity. Lancet 1986; 2: 1219–1220, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 1993; 62: 385–427, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Graham C. H., Kobayashi H., Stankiewicz K. S., Man S., Kapitain S. J., Kerbel R. S. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J. Natl. Cancer Inst. 1994; 86: 975–982, [PUBMED], [INFOTRIEVE], [CSA]
- Granvil C. P., Madan A., Sharkawi M., Parkinson A., Wainer I. W. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab. Dispos. 1999; 27: 533–541, [PUBMED], [INFOTRIEVE], [CSA]
- Graziano S. L., Valone F. H., Herndon J. E., 2nd, Crawford J., Richards F., 2nd, Rege V. B., Clamon G., Green M. R. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a cancer and leukemia group B study. Lung. Cancer. 1996; 14: 315–329, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Greco F. A. Evolving role of oral chemotherapy for the treatment of patients with neoplasms. Oncology 1998; 12: 43–50, [PUBMED], [INFOTRIEVE], [CSA]
- Gregory S. A., Trumper L. Chemotherapy dose intensity in non-Hodgkin’s lymphoma: is dose intensity an emerging paradigm for better outcomes?. Ann. Oncol. 2005; 16, [CROSSREF], [CSA]
- Griffiths L., Binley K., Iqball S., Kan O., Maxwell P., Ratcliffe P., Lewis C., Harris A., Kingsman S., Naylor S. The macrophage – a novel system to deliver gene therapy to pathological hypoxia. Gene Ther 2000; 7: 255–262, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gunsilius E., Gierlich T., Mross K., Gastl G., Unger C. Palliative chemotherapy in pretreated patients with advanced cancer: oral trofosfamide is effective in ovarian carcinoma. Cancer Invest 2001; 19: 808–811, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Gurtoo H. L., Hipkens J. H., Sharma S. D. Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide. Cancer Res 1981; 41: 3584–3591, [PUBMED], [INFOTRIEVE], [CSA]
- Gurtoo H. L., Marinello A. J., Berrigan M. J., Bansal S. K., Paul B., Pavelic Z. P., Struck R. F. Effect of thiols on toxicity and carcinostatic activity of cyclophosphamide. Semin. Oncol. 1983; 10: 35–45, [PUBMED], [INFOTRIEVE], [CSA]
- Haas J. F., Kittelmann B., Mehnert W. H., Staneczek W., Mohner M., Kaldor J. M., Day N. E. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br. J. Cancer. 1987; 55: 213–218, [PUBMED], [INFOTRIEVE], [CSA]
- Haase D., Binder C., Bunger J., Fonatsch C., Streubel B., Schnittger S., Griesinger F., Westphal G., Schoch C., Knopp A., Berkovicz D., Krieger O., Wormann B., Hilgers R., Hallier E., Schulz T. Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1. Leuk. Res. 2002; 26: 249–254, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000; 105: 1045–1047, [PUBMED], [INFOTRIEVE], [CSA]
- Hansen W. K., Kelley M. R. Review of mammalian DNA repair and translational implications. J. Pharmacol. Exp. Ther. 2000; 295: 1–9, [PUBMED], [INFOTRIEVE], [CSA]
- Harper P. Current clinical practices for ovarian cancers. Semin. Oncol. 2002; 29: 3–6, [PUBMED], [INFOTRIEVE], [CSA]
- Hartley J. M., Hansen L., Harland S. J., Nicholson P. W., Pasini F., Souhami R. L. Metabolism of ifosfamide during a 3 day infusion. Br. J. Cancer. 1994; 69: 931–936, [PUBMED], [INFOTRIEVE], [CSA]
- Hartley J. M., Spanswick V. J., Gander M., Giacomini G., Whelan J., Souhami R. L., Hartley J. A. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin. Cancer Res. 1999; 5: 507–512, [PUBMED], [INFOTRIEVE], [CSA]
- Hassan M., Svensson U. S., Ljungman P., Bjorkstrand B., Olsson H., Bielenstein M., Abdel-Rehim M., Nilsson C., Johansson M., Karlsson M. O. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br. J. Clin. Pharmacol. 1999; 48: 669–677, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Haubitz M., Bohnenstengel F., Brunkhorst R., Schwab M., Hofmann U., Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002; 61: 1495–1501, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hayes J. D., Flanagan J. U., Jowsey I. R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005; 45: 51–88, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hellerstedt B., Pienta K. J., Redman B. G., Esper P., Dunn R., Fardig J., Olson K., Smith D. C. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer 2003; 98: 1603–1610, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hempel G., Krumpelmann S., May-Manke A., Hohenlochter B., Blaschke G., Jurgens H., Boos J. Pharmacokinetics of trofosfamide and its dechloroethylated metabolites. Cancer Chemother. Pharmacol. 1997; 40: 45–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hermans I. F., Chong T. W., Palmowski M. J., Harris A. L., Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003; 63: 8408–8413, [PUBMED], [INFOTRIEVE], [CSA]
- Highley M. S., De Bruijn E. A. Erythrocytes and the transport of drugs and endogenous compounds. Pharm. Res. 1996; 13: 186–195, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Highley M. S., Harper P. G., Slee P. H., deBruijn E. Preferential location of circulating activated cyclophosphamide within the erythrocyte. Int. J. Cancer. 1996; 65: 711–712, [PUBMED], [INFOTRIEVE], [CSA]
- Highley M. S., Momerency G., Van Cauwenberghe K., Van Oosterom A. T., de Bruijn E. A., Maes R. A., Blake P., Mansi J., Harper P. G. Formation of chloroethylamine and 1,3-oxazolidine-2-one following ifosfamide administration in humans. Drug Metab. Dispos. 1995; 23: 433–437, [PUBMED], [INFOTRIEVE], [CSA]
- Highley M. S., Schrijvers D., Van Oosterom A. T., Harper P. G., Momerency G., Van Cauwenberghe K., Maes R. A., De Bruijn E. A., Edelstein M. B. Activated oxazaphosphorines are transported predominantly by erythrocytes. Ann. Oncol. 1997; 8: 1139–1144, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hill D. L., Laster W. R., Jr., Kirk M. C., el-Dareer S., Struck R. F. Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite. Cancer Res 1973; 33: 1016–1022, [PUBMED], [INFOTRIEVE], [CSA]
- Hilton J. Deoxyribonucleic acid crosslinking by 4-hydroperoxycyclophosphamide in cyclophosphamide-sensitive and -resistant L1210 cells. Biochem. Pharmacol. 1984a; 33: 1867–1872, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984b; 44: 5156–5160, [PUBMED], [INFOTRIEVE], [CSA]
- Hipkens J. H., Struck R. F., Gurtoo H. L. Role of aldehyde dehydrogenase in the metabolism-dependent biological activity of cyclophosphamide. Cancer Res 1981; 41: 3571–3583, [PUBMED], [INFOTRIEVE], [CSA]
- Hiratsuka M., Hinai Y., Konno Y., Nozawa H., Konno S., Mizugaki M. Three novel single nucleotide polymorphisms (SNPs) of the CYP2B6 gene in Japanese individuals. Drug Metab. Pharmacokinet. 2004; 19: 155–158, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hirouchi M., Suzuki H., Itoda M., Ozawa S., Sawada J., Ieiri I., Ohtsubo K., Sugiyama Y. Characterization of the cellular localization, expression level, and function of SNP variants of MRP2/ABCC2. Pharm. Res. 2004; 21: 742–748, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hobdy E. M., Kraut E., Masters G., Blum K., McKeon A., Byrd B., Davies M., Beaulieu N., Murren J. R. A phase II study of topotecan and cyclophosphamide with G-CSF in patients with advanced small cell lung cancer. Cancer Biol. Ther. 2004; 3: 89–93, [PUBMED], [INFOTRIEVE], [CSA]
- Hoefer H., Scheef W., Titscher R., Kokron O. [Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author’s transl)]. Osterr Z Onkol 1974; 1: 3–7, [PUBMED], [INFOTRIEVE], [CSA]
- Hohorst H. J., Draeger U., Peter G., Voelcker G. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity. Cancer Treat. Rep. 1976; 60: 309–315, [PUBMED], [INFOTRIEVE], [CSA]
- Hohorst H. J., Ziemann A., Brock N. 4-Ketocyclophosphamide, a metabolite of cyclophosphamide. Formation, chemical and biological properties. Arzneimittelforschung 1971; 21: 1254–1257, [PUBMED], [INFOTRIEVE], [CSA]
- Holm K. A., Kindberg C. G., Stobaugh J. F., Slavik M., Riley C. M. Stereoselective pharmacokinetics and metabolism of the enantiomers of cyclophosphamide. Preliminary results in humans and rabbits. Biochem. Pharmacol. 1990; 39: 1375–1384, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hon Y. Y., Evans W. E. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin. Chem. 1998; 44: 388–400, [PUBMED], [INFOTRIEVE], [CSA]
- Honjo I., Suou T., Hirayama C. Hepatotoxicity of cyclophosphamide in man: pharmacokinetic analysis. Res. Commun. Chem. Pathol. Pharmacol. 1988; 61: 149–165, [PUBMED], [INFOTRIEVE], [CSA]
- Houssiau F. A., Vasconcelos C., D’Cruz D., Sebastiani G. D., Garrido Ed Ede R., Danieli M. G., Abramovicz D., Blockmans D., Mathieu A., Direskeneli H., Galeazzi M., Gul A., Levy Y., Petera P., Popovic R., Petrovic R., Sinico R. A., Cattaneo R., Font J., Depresseux G., Cosyns J. P., Cervera R. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121–2131, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hsu L. C., Chang W. C., Yoshida A. Human aldehyde dehydrogenase genes, ALDH7 and ALDH8: genomic organization and gene structure comparison. Gene 1997; 189: 89–94, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Huang Z., Roy P., Waxman D. J. Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochem. Pharmacol. 2000; 59: 961–972, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Huitema A. D., Kerbusch T., Tibben M. M., Rodenhuis S., Beijnen J. H. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother. Pharmacol. 2000; 46: 119–127, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Huitema A. D., Mathot R. A., Tibben M. M., Rodenhuis S., Beijnen J. H. A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J. Pharmacokinet. Pharmacodyn. 2001; 28: 211–230, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hunt S. Technology evaluation: MetXia-P450, Oxford Biomedica. Curr. Opin. Mol. Ther. 2001; 3: 595–598, [PUBMED], [INFOTRIEVE], [CSA]
- Hussain S. A., James N. D. The systemic treatment of advanced and metastatic bladder cancer. Lancet. Oncol. 2003; 4: 489–497, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Hustert E., Zibat A., Presecan-Siedel E., Eiselt R., Mueller R., Fuss C., Brehm I., Brinkmann U., Eichelbaum M., Wojnowski L., Burk O. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 2001; 29: 1454–1459, [PUBMED], [INFOTRIEVE], [CSA]
- Ikezawa Y., Nakazawa M., Tamura C., Takahashi K., Minami M., Ikezawa Z. Cyclophosphamide decreases the number, percentage and the function of CD25(+) CD4(+) regulatory T cells, which suppress induction of contact hypersensitivity. J. Dermatol. Sci. 2005; 39, [CROSSREF], [CSA]
- Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol 2005; 207(supp), [CSA]
- Inoue M., Fujita M., Enomoto T., Tanizawa O. Long-term follow-up of patients with advanced ovarian cancers treated with intermittent administration of combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Int. J. Gynecol. Cancer. 1995; 5: 374–380, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ito H., Duxbury M., Zinner M. J., Ashley S. W., Whang E. E. Glucose transporter-1 gene expression is associated with pancreatic cancer invasiveness and MMP-2 activity. Surgery 2004; 136: 548–556, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ito K., Oleschuk C. J., Westlake C., Vasa M. Z., Deeley R. G., Cole S. P. Mutation of Trp1254 in the multispecific organic anion transporter, multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J. Biol. Chem. 2001a; 276: 38108–38114, [PUBMED], [INFOTRIEVE], [CSA]
- Ito K., Suzuki H., Hirohashi T., Kume K., Shimizu T., Sugiyama Y. Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR. Am. J. Physiol. 1997; 272: G16–G22, [PUBMED], [INFOTRIEVE], [CSA]
- Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001b; 11: 175–184, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001c; 11: 175–184, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jantunen E., Putkonen M., Nousiainen T., Pelliniemi T. T., Mahlamaki E., Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347–351, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jarman M. Formation of 4-ketocyclophosphamide by the oxidation of cyclophosphamide with KMnO4. Experientia 1973; 29: 812–814, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jinno H., Tanaka-Kagawa T., Ohno A., Makino Y., Matsushima E., Hanioka N., Ando M. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 2003; 31: 398–403, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Johnstone E. C., Lind M. J., Griffin M. J., Boddy A. V. Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. Cancer Chemother. Pharmacol. 2000; 46: 433–441, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Joqueviel C., Martino R., Gilard V., Malet-Martino M., Canal P., Niemeyer U. Urinary excretion of cyclophosphamide in humans, determined by phosphorus-31 nuclear magnetic resonance spectroscopy. Drug Metab. Dispos. 1998; 26: 418–428, [PUBMED], [INFOTRIEVE], [CSA]
- Josting A., Sieniawski M., Glossmann J. P., Staak O., Nogova L., Peters N., Mapara M., Dorken B., Ko Y., Metzner B., Kisro J., Diehl V., Engert A. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin’s lymphoma: results of a multicenter phase II study. Ann. Oncol. 2005; 16: 1359–1365, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jounaidi Y., Hecht J. E., Waxman D. J. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. Cancer Res 1998; 58: 4391–4401, [PUBMED], [INFOTRIEVE], [CSA]
- Jounaidi Y., Waxman D. J. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res 2001; 61: 4437–4444, [PUBMED], [INFOTRIEVE], [CSA]
- Jounaidi Y., Waxman D. J. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res 2004; 64: 292–303, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Juma F., Ogada T. Pharmacokinetics of cyclophosphamide in Kenyan Africans. Br. J. Clin. Pharmacol. 1983; 16: 61–63, [PUBMED], [INFOTRIEVE], [CSA]
- Juma F. D., Rogers H. J., Trounce J. R. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br. J. Clin. Pharmacol. 1979; 8: 209–217, [PUBMED], [INFOTRIEVE], [CSA]
- Juma F. D., Rogers H. J., Trounce J. R. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur. J. Clin. Pharmacol. 1981; 19: 443–451, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kaijser G. P., Beijnen J. H., Bult A., Underberg W. J. Ifosfamide metabolism and pharmacokinetics (review). Anticancer Res 1994; 14: 517–531, [PUBMED], [INFOTRIEVE], [CSA]
- Kaijser G. P., Beijnen J. H., Jeunink E. L., Bult A., Keizer H. J., de Kraker J., Underberg W. J. Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma. J. Chromatogr. 1993a; 614: 253–259, [PUBMED], [INFOTRIEVE], [CSA]
- Kaijser G. P., De Kraker J., Bult A., Underberg W. J., Beijnen J. H. Pharmacokinetics of ifosfamide and some metabolites in children. Anticancer Res 1998; 18: 1941–1949, [PUBMED], [INFOTRIEVE], [CSA]
- Kaijser G. P., Keizer H. J., Beijnen J. H., Bult A., Underberg W. J. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide. Anticancer Res 1996; 16: 3247–3257, [PUBMED], [INFOTRIEVE], [CSA]
- Kaijser G. P., Korst A., Beijnen J. H., Bult A., Underberg W. J. The analysis of ifosfamide and its metabolites (review). Anticancer Res 1993b; 13: 1311–1324, [PUBMED], [INFOTRIEVE], [CSA]
- Kamen B. A., Frenkel E., Colvin O. M. Ifosfamide: should the honeymoon be over?. J. Clin. Oncol. 1995; 13: 307–309, [PUBMED], [INFOTRIEVE], [CSA]
- Kan O., Griffiths L., Baban D., Iqball S., Uden M., Spearman H., Slingsby J., Price T., Esapa M., Kingsman S., Kingsman A., Slade A., Naylor S. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene. Ther. 2001; 8: 473–482, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kan O., Kingsman S., Naylor S. Cytochrome P450-based cancer gene therapy: current status. Expert Opin. Biol. Ther. 2002; 2: 857–868, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Karanth M., Chakrabarti S., Lovell R. A., Harvey C., Holder K., McConkey C. C., McDonald D., Fegan C. D., Milligan D. W. A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone. Bone Marrow Transplant 2004; 34: 399–403, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kartenbeck J., Leuschner U., Mayer R., Keppler D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996; 23: 1061–1066, [PUBMED], [INFOTRIEVE], [CSA]
- Kasamon Y. L., Jones R. J., Piantadosi S., Ambinder R. F., Abrams R. A., Borowitz M. J., Morrison C., Smith B. D., Flinn I. W. High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. Biol. Blood Marrow Transplant. 2005; 11: 93–100, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kastan M. B., Schlaffer E., Russo J. E., Colvin O. M., Civin C. I., Hilton J. Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 1990; 75: 1947–1950, [PUBMED], [INFOTRIEVE], [CSA]
- Kehrer J. P., Biswal S. S. The molecular effects of acrolein. Toxicol. Sci. 2000; 57: 6–15, [PUBMED], [INFOTRIEVE], [CSA]
- Kennedy M. J., Zahurak M. L., Donehower R. C., Noe D., Grochow L. B., Sartorius S., Chen T. L., Bowling K., Duerr M., Rowinsky E. K. Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet. Clin. Cancer Res. 1998; 4: 349–356, [PUBMED], [INFOTRIEVE], [CSA]
- Kerbusch T., de Kraker J., Keizer H. J., van Putten J. W., Groen H. J., Jansen R. L., Schellens J. H., Beijnen J. H. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin. Pharmacokinet. 2001a; 40: 41–62, [PUBMED], [INFOTRIEVE], [CSA]
- Kerbusch T., de Kraker J., Mathjt R. A., Beijne J. H. Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach. Clin. Pharmacokinet. 2001b; 40: 615–625, [PUBMED], [INFOTRIEVE], [CSA]
- Kerbusch T., Groenewegen G., Mathot R. A., Herben V. M., ten Bokkel Huinink W. W., Swart M., Ambaum B., Rosing H., Jansen S., Voest E. E., Beijnen J. H., Schellens J. H. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. Br. J. Cancer. 2004; 90: 2268–2277, [PUBMED], [INFOTRIEVE], [CSA]
- Kerbusch T., Huitema A. D., Ouwerkerk J., Keizer H. J., Mathot R. A., Schellens J. H., Beijnen J. H. Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM. Br. J. Clin. Pharmacol. 2000; 49: 555–561, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kerbusch T., Jansen R. L., Mathot R. A., Huitema A. D., Jansen M., van Rijswijk R. E., Beijnen J. H. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin. Pharmacol. Ther. 2001c; 70: 132–141, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kerbusch T., Mathjt R. A., Keizer H. J., Ouwerkerk J., Rodenhuis S., Schellens J. H., Beijnen J. H. Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. Eur. J. Clin. Pharmacol. 2001d; 57: 467–477, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kerbusch T., Mathot R. A., Keizer H. J., Kaijser G. P., Schellens J. H., Beijnen J. H. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab. Dispos. 2001e; 29: 967–975, [PUBMED], [INFOTRIEVE], [CSA]
- Kersun L. S., Wimmer R. S., Hoot A. C., Meadows A. T. Secondary malignant neoplasms of the bladder after cyclophosphamide treatment for childhood acute lymphocytic leukemia. Pediatr. Blood Cancer. 2004; 42: 289–291, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Keystone E. C. B cells in rheumatoid arthritis: from hypothesis to the clinic. Rheumatology (Oxford) 2005; 44(Suppl 2)ii8–ii12, [CROSSREF], [CSA]
- Kharasch E. D., Hoffer C., Walker A., Sheffels P. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clin. Pharmacol. Ther. 2003; 73: 199–208, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kim D. W., Jo Y. H., Kim J. H., Wu H. G., Rhee C. S., Lee C. H., Kim T. Y., Heo D. S., Bang Y. J., Kim N. K. Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma. Cancer 2004; 101: 2257–2260, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kim D. Y., Lee K. W., Yun T., Park S. R., Jung J. Y., Kim D. W., Kim T. Y., Heo D. S., Bang Y. J., Kim N. K. Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn. J. Clin. Oncol. 2003; 33: 608–612, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kivisto K. T., Fritz P., Linder A., Friedel G., Beaune P., Kroemer H. K. Immunohistochemical localization of cytochrome P450 3A in human pulmonary carcinomas and normal bronchial tissue. Histochem. Cell. Biol. 1995; 103: 25–29, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Klastersky J. Side effects of ifosfamide. Oncology 2003; 65(Suppl 2)7–10, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kobayashi K., Morita J., Chiba K., Wanibuchi A., Kimura M., Irie S., Urae A., Ishizaki T. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics 2004; 14: 549–556, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kobylinska K., Kobylinska M., Sobik B. Pharmacokinetics of (−)-(S)-bromofosfamide after intravenous and oral administration in mice. Arzneimittelforschung 2001a; 51: 596–599, [PUBMED], [INFOTRIEVE], [CSA]
- Kobylinska K., Koralewski P., Sobik B., Gasiorek M., Kobylinska M. Pharmacokinetics and toxicity of oral (−)-(S)-bromofosfamide in lung cancer patients. Arzneimittelforschung 2001b; 51: 600–603, [PUBMED], [INFOTRIEVE], [CSA]
- Koelling T. M., Yeager A. M., Hilton J., Haynie D. T., Wiley J. M. Development and characterization of a cyclophosphamide-resistant subline of acute myeloid leukemia in the Lewis x Brown Norway hybrid rat. Blood 1990; 76: 1209–1213, [PUBMED], [INFOTRIEVE], [CSA]
- Kohn F. R., Landkamer G. J., Manthey C. L., Ramsay N. K., Sladek N. E. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines. Cancer Res 1987; 47: 3180–3185, [PUBMED], [INFOTRIEVE], [CSA]
- Kohn F. R., Sladek N. E. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557). Biochem. Pharmacol. 1987; 36: 2805–2811, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kollmannsberger C., Brugger W., Hartmann J. T., Maurer F., Bohm P., Kanz L., Bokemeyer C. Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma. Anticancer Drugs 1999; 10: 453–456, [PUBMED], [INFOTRIEVE], [CSA]
- Kool M., van der Linden M., de Haas M., Scheffer G. L., de Vree J. M., Smith A. J., Jansen G., Peters G. J., Ponne N., Scheper R. J., Elferink R. P., Baas F., Borst P. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl. Acad. Sci. USA. 1999; 96: 6914–6919, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Koren G., Beatty K., Seto A., Einarson T. R., Lishner M. The effects of impaired liver function on the elimination of antineoplastic agents. Ann. Pharmacother. 1992; 26: 363–371, [PUBMED], [INFOTRIEVE], [CSA]
- Kosmas C., Tsavaris N., Malamos N., Stavroyianni N., Gregoriou A., Rokana S., Polyzos A. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer. Br. J. Cancer. 2003; 88: 1168–1174, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kunkel M., Reichert T. E., Benz P., Lehr H. A., Jeong J. H., Wieand S., Bartenstein P., Wagner W., Whiteside T. L. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003; 97: 1015–1024, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kurokawa T., Yoshida Y., Kawahara K., Tsuchida T., Okazawa H., Fujibayashi Y., Yonekura Y., Kotsuji F. Expression of GLUT-1 glucose transfer, cellular p_roliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int. J. Cancer. 2004; 109: 926–932, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kurowski V., Cerny T., Kupfer A., Wagner T. Metabolism and pharmacokinetics of oral and intravenous ifosfamide. J. Cancer Res. Clin. Oncol. 1991; 117(Suppl 4)S148–153, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kusnierczyk H., Konarski L., Kowalski P., Radzikowski C. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide. Arch. Immunol. Ther. Exp. (Warsz) 1997; 45: 79–85, [CSA]
- Kusnierczyk H., Pajtasz-Piasecka E., Radzikowski C. Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model. Med. Oncol. 1999; 16: 267–278, [PUBMED], [INFOTRIEVE], [CSA]
- Lacki J. K., Leszczynski P., Mackiewicz S. H. Intravenous cyclophosphamide combined with methylprednisolone in the treatment of severe refractory rheumatoid arthritis: the effect on lymphocytes. J. Investig. Allergol. Clin. Immunol. 1996; 6: 232–236, [PUBMED], [INFOTRIEVE], [CSA]
- Lacki J. K., Mackiewicz S. H., Leszczynski P., Muller W. The effect of intravenous cyclophosphamide pulse on peripheral blood lymphocytes in lupus erythematosus patients. Rheumatol. Int. 1997; 17: 55–60, [PUBMED], [INFOTRIEVE], [CSA]
- Lai L., Tan T. M. Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues. Biochem. J. 2002; 361: 497–503, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lang T., Klein K., Fischer J., Nussler A. K., Neuhaus P., Hofmann U., Eichelbaum M., Schwab M., Zanger U. M. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399–415, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Larrey D., Pageaux G. P. Genetic predisposition to drug-induced hepatotoxicity. J. Hepatol. 1997; 26: 12–21, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Latz D., Nassar N., Frank R. Trofosfamide in the palliative treatment of cancer: a review of the literature. Onkologie 2004; 27: 572–576, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lazzarino M., Arcaini L., Orlandi E., Iacona I., Bernasconi P., Calatroni S., Varettoni M., Isa L., Brusamolino E., Bonfichi M., Passamonti F., Burcheri S., Pascutto C., Regazzi M. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma. Oncology 2005; 68: 146–153, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Leandro M. J., Edwards J. C., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann. Rheum. Dis. 2002; 61: 883–888, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lee C. R., Goldstein J. A., Pieper J. A. Cytochrome P4502C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251–263, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lehmann J. M., McKee D. D., Watson M. A., Willson T. M., Moore J. T., Kliewer S. A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 1998; 102: 1016–1023, [PUBMED], [INFOTRIEVE], [CSA]
- Lelieveld P., van Putten L. M. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271). Cancer Treat. Rep. 1976; 60: 373–379, [PUBMED], [INFOTRIEVE], [CSA]
- Lennard L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br. J. Clin. Pharmacol. 1999; 47: 131–143, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lennard L. Therapeutic drug monitoring of cytotoxic drugs. Br. J. Clin. Pharmacol. 2001; 52(Suppl 1)75S–87S, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Leslie E. M., Letourneau I. J., Deeley R. G., Cole S. P. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 2003; 42: 5214–5224, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Levine M. N., Pritchard K. I., Bramwell V. H., Shepherd L. E., Tu D., Paul N. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J. Clin. Oncol. 2005; 23: 5166–5170, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lewis L. D. A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles. Br. J. Clin. Pharmacol. 1996; 42: 179–186, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lewis L. D., Fitzgerald D. L., Harper P. G., Rogers H. J. Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br. J. Clin. Pharmacol. 1990; 30: 725–732, [PUBMED], [INFOTRIEVE], [CSA]
- Lim Y. P., Liu C. H., Shyu L. J., Huang J. D. Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet. Genomics. 2005; 15: 337–341, [PUBMED], [INFOTRIEVE], [CSA]
- Lin J., Shiu W., Leung W. T., Tao M., Leung N., Lau W. Y., Li A. K. Phase II study of high-dose ifosfamide in hepatocellular carcinoma. Cancer Chemother. Pharmacol. 1993; 31: 338–339, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lind M. J., Margison J. M., Cerny T., Thatcher N., Wilkinson P. M. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res 1989a; 49: 753–757, [PUBMED], [INFOTRIEVE], [CSA]
- Lind M. J., Margison J. M., Cerny T., Thatcher N., Wilkinson P. M. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother. Pharmacol. 1989b; 25: 139–142, [PUBMED], [INFOTRIEVE], [CSA]
- Lindemann A., Hoffken K., Schmidt R. E., Diehl V., Kloke O., Gamm H., Hayungs J., Oster W., Bohm M., Kolitz J. E. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol. Immunother. 1989; 28: 275–281, [PUBMED], [INFOTRIEVE], [CSA]
- Lindley C., Hamilton G., McCune J. S., Faucette S., Shord S. S., Hawke R. L., Wang H., Gilbert D., Jolley S., Yan B., LeCluyse E. L. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab. Dispos. 2002; 30: 814–822, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lippman M. E., Sorace R. A., Bagley C. S., Danforth D. W., Jr., Lichter A., Wesley M. N. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery. NCI Monogr 1986; 153–159, [CSA]
- Loeffler M., Kruger J. A., Reisfeld R. A. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 2005; 65: 5027–5030, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lohr M., Hummel F., Faulmann G., Ringel J., Saller R., Hain J., Gunzburg W. H., Salmons B. Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century. Cancer Chemother. Pharmacol. 2002; 49(Suppl 1)S21–4, [PUBMED], [INFOTRIEVE], [CSA]
- Lohr M., Kroger J. C., Hoffmeyer A., Freund M., Hain J., Holle A., Knofel W. T., Liebe S., Nizze H., Renner M. Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial. Cancer Ther 2003; 1: 121–131, [CSA]
- Lokiec F., Santoni J., Weill S., Tubiana-Hulin M. Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. Anticancer Drugs 1996; 7: 893–896, [PUBMED], [INFOTRIEVE], [CSA]
- Lorigan P., Woll P. J., O’Brien M. E., Ashcroft L. F., Sampson M. R., Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J. Natl. Cancer Inst. 2005; 97: 666–674, [PUBMED], [INFOTRIEVE], [CSA]
- Ludeman S. M. The chemistry of the metabolites of cyclophosphamide. Curr. Pharm. Des. 1999; 5: 627–643, [PUBMED], [INFOTRIEVE], [CSA]
- Ludeman S. M., Gamcsik M. P. Mechanisms of resistance against cyclophosphamide and ifosfamide: can they be overcome without sacrificing selectivity?. Cancer Treat. Res. 2002; 112: 177–197, [PUBMED], [INFOTRIEVE], [CSA]
- Lundin J., Osterborg A., Bjorkholm M., Bjorkstrand B., Celsing F., Hjalmar V., Linder O., Luthman M., Merup M., Tidefelt U., Mellstedt H. Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60–75 years of age with multiple myeloma stages II and III. Hematol. J. 2003; 4: 248–252, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lutsiak M. E., Semnani R. T., De Pascalis R., Kashmiri S. V., Schlom J., Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005; 105: 2862–2868, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Macheda M. L., Rogers S., Best J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 2005; 202: 654–662, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Machida I., Inagaki Y., Suzuki S., Hayashi H., Wakusawa S. Mutation analysis of the multidrug resistance protein 2 (MRP2) gene in a Japanese patient with Dubin-Johnson syndrome. Hepatol. Res. 2004; 30: 86–90, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Machida I., Wakusawa S., Sanae F., Hayashi H., Kusakabe A., Ninomiya H., Yano M., Yoshioka K. Mutational analysis of the MRP2 gene and long-term follow-up of Dubin-Johnson syndrome in Japan. J. Gastroenterol. 2005; 40: 366–370, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Magni M., Shammah S., Schiro R., Mellado W., Dalla-Favera R., Gianni A. M. Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood 1996; 87: 1097–1103, [PUBMED], [INFOTRIEVE], [CSA]
- Majado M. J., Gonzalez C., Marin L., Morales A., Moya M. R., Candel R. Second mobilization of peripheral blood progenitor cells in patients with poor first mobilization. Transplant Proc 2003; 35: 2027–2028, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Maki P. A., Sladek N. E. Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide. Biochem. Pharmacol. 1993; 45: 231–239, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Malik I. A., Mehboobali N., Iqbal M. P. Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer. Cancer Chemother. Pharmacol. 1997; 39: 561–565, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Man S., Bocci G., Francia G., Green S. K., Jothy S., Hanahan D., Bohlen P., Hicklin D. J., Bergers G., Kerbel R. S. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002; 62: 2731–2735, [PUBMED], [INFOTRIEVE], [CSA]
- Mancuso P., Calleri A., Cassi C., Gobbi A., Capillo M., Pruneri G., Martinelli G., Bertolini F. Circulating endothelial cells as a novel marker of angiogenesis. Adv. Exp. Med. Biol. 2003; 522: 83–97, [PUBMED], [INFOTRIEVE], [CSA]
- Manegold C., Bischoff H., Fischer J. R., Lochner S., Peukert M., Schmahl A., Drings P. Oral ifosfamide-mesna: a clinical investigation in advanced non-small-cell lung cancer. Ann. Oncol. 1992; 3: 723–726, [PUBMED], [INFOTRIEVE], [CSA]
- Manegold C., Drings P., Pawinski A., Lentz M. A., van Glabbeke M., van Zandwijk N., Bachmann P., Schnaars Y., Skacel Z., Zatloukal P., Dolensky J., Jackevicius A., Petruzelka L., Giaccone G. Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group. Ann. Oncol. 1996; 7: 637–639, [PUBMED], [INFOTRIEVE], [CSA]
- Manthey C. L., Sladek N. E. Aldehyde dehydrogenase-catalyzed bioinactivation of cyclophosphamide. Prog. Clin. Biol. Res. 1989; 290: 49–63, [PUBMED], [INFOTRIEVE], [CSA]
- Manzano R. G., Wright K. A., Twentyman P. R. Modulation by acrolein and chloroacetaldehyde of multidrug resistance mediated by the multidrug resistance-associated protein (MRP). Clin. Cancer Res. 1996; 2: 1321–1326, [PUBMED], [INFOTRIEVE], [CSA]
- Martin A. D., Beer R. W., Bosanquet A. G., Gilby E. D. The effect of alkylating agents and other drugs on the accumulation of melphalan by murine L1210 leukaemia cells in vitro. Biochem. Pharmacol. 1982; 31: 2727–2732, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Martin H., Sarsat J. P., de Waziers I., Housset C., Balladur P., Beaune P., Albaladejo V., Lerche-Langrand C. Induction of cytochrome P450 2B6 and 3A4 expression by phenobarbital and cyclophosphamide in cultured human liver slices. Pharm. Res. 2003; 20: 557–568, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Masta A., Gray P. J., Phillips D. R. Nitrogen mustard inhibits transcription and translation in a cell free system. Nucleic. Acids Res. 1995; 23: 3508–3515, [PUBMED], [INFOTRIEVE], [CSA]
- Masters G. A., Hoffman P. C., Drinkard L. C., Samuels B. L., Golomb H. M., Vokes E. E. A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung. Semin. Oncol. 1998; 25: 8–14, [PUBMED], [INFOTRIEVE], [CSA]
- Matsunaga T., Sakamaki S., Kuga T., Kuroda H., Kusakabe T., Akiyama T., Konuma Y., Hirayama Y., Kobune M., Kato J., Sasaki K., Kogawa K., Koyama R., Niitsu Y. GST-pi gene-transduced hematopoietic progenitor cell transplantation overcomes the bone marrow toxicity of cyclophosphamide in mice. Hum. Gene. Ther. 2000; 11: 1671–1681, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mattern J., Eichhorn U., Kaina B., Volm M. O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int. J. Cancer. 1998; 77: 919–922, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Maurel J., Buesa J., Lopez-Pousa A., del Muro X. G., Quintana M. J., Martin J., Casado A., Martinez-Trufero J., de Las Penas R., Balana C. Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias–a study of the Spanish group for research on sarcomas (GEIS). J. Surg. Oncol. 2004; 88: 44–49, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mayer J., Vasova I., Koristek Z., Navratil M., Klabusay M., Doubek M., Vorlicek J., Cernilova I., Vodvarka P., Petrakova K. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Eur. J. Haematol. Suppl. 2001; 21–27, [CSA]
- May-Manke A., Kroemer H., Hempel G., Bohnenstengel F., Hohenlochter B., Blaschke G., Boos J. Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide. Cancer Chemother. Pharmacol. 1999; 44: 327–334, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McCune J. S., Risler L. J., Phillips B. R., Thummel K. E., Blough D., Shen D. D. Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation. Drug Metab. Dispos 2005, [CSA]
- McErlane V., Yakkundi A., McCarthy H. O., Hughes C. M., Patterson L. H., Hirst D. G., Robson T., McKeown S. R. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N. J. Gene. Med. 2005; 7: 851–859, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McLeod H. L. Therapeutic drug monitoring opportunities in cancer therapy. Pharmacol. Ther. 1997; 74: 39–54, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McNiel N. O., Morgan L. R., Jr. The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. Int. J. Clin. Pharmacol. Ther. Toxicol. 1981; 19: 490–493, [PUBMED], [INFOTRIEVE], [CSA]
- Medina R. A., Owen G. I. Glucose transporters: expression, regulation and cancer. Biol. Res. 2002; 35: 9–26, [PUBMED], [INFOTRIEVE], [CSA]
- Mendez L. E., Manci N., Cantuaria G., Gomez-Marin O., Penalver M., Braunschweiger P., Nadji M. Expression of glucose transporter-1 in cervical cancer and its precursors. Gynecol. Oncol. 2002; 86: 138–143, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Miller L., Kobrinsky N. L., Goldenberg G. J. Modulation of membrane transport of alkylating agents and amino acids by an analog of vasopressin in murine L5178Y lymphoblasts in vitro. Biochem. Pharmacol. 1987; 36: 169–176, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Misiura K. Synthesis of potential metabolites of (S)-(−)-bromofosfamide. Pharmazie 2004; 59: 668–672, [PUBMED], [INFOTRIEVE], [CSA]
- Momerency G., Van Cauwenberghe K., Highley M. S., Harper P. G., Van Oosterom A. T., de Bruijn E. A. Partitioning of ifosfamide and its metabolites between red blood cells and plasma. J. Pharm. Sci. 1996; 85: 262–265, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moore L. B., Parks D. J., Jones S. A., Bledsoe R. K., Consler T. G., Stimmel J. B., Goodwin B., Liddle C., Blanchard S. G., Willson T. M., Collins J. L., Kliewer S. A. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J. Biol. Chem. 2000; 275: 15122–15127, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moore M. J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 1991; 20: 194–208, [PUBMED], [INFOTRIEVE], [CSA]
- Moore M. J., Erlichman C. Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy. Clin. Pharmacokinet. 1987; 13: 205–227, [PUBMED], [INFOTRIEVE], [CSA]
- Moore M. J., Erlichman C., Thiessen J. J., Bunting P. S., Hardy R., Kerr I., Soldin S. Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother. Pharmacol. 1994; 33: 472–476, [PUBMED], [INFOTRIEVE], [CSA]
- Mor-Cohen R., Zivelin A., Rosenberg N., Shani M., Muallem S., Seligsohn U. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J. Biol. Chem. 2001; 276: 36923–36930, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moreb J., Zucali J. R., Zhang Y., Colvin M. O., Gross M. A. Role of aldehyde dehydrogenase in the protection of hematopoietic progenitor cells from 4-hydroperoxycyclophosphamide by interleukin 1 beta and tumor necrosis factor. Cancer Res 1992; 52: 1770–1774, [PUBMED], [INFOTRIEVE], [CSA]
- Moreb J. S., Gabr A., Vartikar G. R., Gowda S., Zucali J. R., Mohuczy D. Retinoic acid down-regulates aldehyde dehydrogenase and increases cytotoxicity of 4-hydroperoxycyclophosphamide and acetaldehyde. J. Pharmacol. Exp. Ther. 2005; 312: 339–345, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moreb J. S., Maccow C., Schweder M., Hecomovich J. Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro. J. Pharmacol. Exp. Ther. 2000; 293: 390–396, [PUBMED], [INFOTRIEVE], [CSA]
- Moreb J. S., Schweder M., Gray B., Zucali J., Zori R. In vitro selection for K562 cells with higher retrovirally mediated copy number of aldehyde dehydrogenase class-1 and higher resistance to 4-hydroperoxycyclophosphamide. Hum. Gene. Ther. 1998; 9: 611–619, [PUBMED], [INFOTRIEVE], [CSA]
- Morgan L. R., Harrison E. F., Hawke J. E., Hunter H. L., Costanzi J. J., Plotkin D., Tucker W. G., Worrall P. M. Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study. Semin. Oncol. 1982; 9: 66–70, [PUBMED], [INFOTRIEVE], [CSA]
- Morgan R. J., Doroshow J. H., Leong L., Schriber J., Shibata S., Forman S., Hamasaki V., Margolin K., Somlo G., Alvarnas J., McNamara M., Longmate J., Raschko J., Chow W., Vasilev S., McGonigle K., Yen Y. Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplant 2001; 28: 859–863, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Morrow C. S., Smitherman P. K., Townsend A. J. Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1–1 (GSTP1–1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem. Pharmacol. 1998; 56: 1013–1021, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Moscow J. A., Swanson C. A., Cowan K. H. Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br. J. Cancer. 1993; 68: 732–737, [PUBMED], [INFOTRIEVE], [CSA]
- Mouridsen H. T., Faber O., Skovsted L. The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide. Cancer 1976; 37: 665–670, [PUBMED], [INFOTRIEVE], [CSA]
- Mulders T. M., Keizer, Ouwerkerk J., van der Velde E. A., Breimer D. D., Mulder G. J. Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. Clin. Cancer Res. 1995; 1: 1525–1536, [PUBMED], [INFOTRIEVE], [CSA]
- Muldoon L. L., Walker-Rosenfeld S. L., Hale C., Purcell S. E., Bennett L. C., Neuwelt E. A. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. J. Pharmacol. Exp. Ther. 2001; 296: 797–805, [PUBMED], [INFOTRIEVE], [CSA]
- Muller M. R., Buschfort C., Thomale J., Lensing C., Rajewsky M. F., Seeber S. DNA repair and cellular resistance to alkylating agents in chronic lymphocytic leukemia. Clin. Cancer Res. 1997; 3: 2055–2061, [PUBMED], [INFOTRIEVE], [CSA]
- Muller M. R., Thomale J., Lensing C., Rajewsky M. F., Seeber S. Chemosensitisation of alkylating agents by pentoxifylline, O6-benzylguanine and ethacrynic acid in haematological malignancies. Anticancer Res 1993; 13: 2155–2159, [PUBMED], [INFOTRIEVE], [CSA]
- Murray G. I., Melvin W. T., Burke M. D. Cytochrome P450 expression in tumours. J. Pathol. 1995; 176: 323–324, [PUBMED], [INFOTRIEVE], [CSA]
- Nagamura F., Takahashi T., Takeuchi M., Iseki T., Ooi J., Tomonari A., Uchimaru K., Takahashi S., Tojo A., Tani K., Asano S. Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 32: 1051–1058, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nakajima T., Takayama T., Miyanishi K., Nobuoka A., Hayashi T., Abe T., Kato J., Sakon K., Naniwa Y., Tanabe H., Niitsu Y. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. J. Pharmacol. Exp. Ther. 2003; 306: 861–869, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nelson R. L., Allen L. M., Creaven P. J. Pharmacokinetics of divided-dose ifosfamide. Clin. Pharmacol. Ther. 1976; 19: 365–370, [PUBMED], [INFOTRIEVE], [CSA]
- Nersessian A. K., Zilfian V. N., Koumkoumadjian V. A. Comparative investigation of cyclophosphamide action on bone marrow cells of the Armenian hamster and 4 other species of rodents. Mutat. Res. 1992; 268: 211–215, [PUBMED], [INFOTRIEVE], [CSA]
- Ng S. S., Figg W. D. Upregulation of endogenous angiogenesis inhibitors: a mechanism of action of metronomic chemotherapy. Cancer Biol. Ther. 2004; 3: 1212–1213, [PUBMED], [INFOTRIEVE], [CSA]
- Nicoletto M. O., Tumolo S., Falci C., Donach M., Visona E., Rosabian A., Nascimben O., Cima G. P., Vinante O., Azzoni P., Fiorentino M. V. A randomized study of epithelial ovarian cancer: Is chemotherapy useful after complete remission?. Int. J. Med. Sci. 2004; 1: 116–125, [PUBMED], [INFOTRIEVE], [CSA]
- Nicolini A., Mancini P., Ferrari P., Anselmi L., Tartarelli G., Bonazzi V., Carpi A., Giardino R. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed. Pharmacother. 2004; 58: 447–450, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Niculescu-Duvaz I. Glufosfamide (Baxter Oncology). Curr. Opin. Investig. Drugs. 2002; 3: 1527–1532, [PUBMED], [INFOTRIEVE], [CSA]
- Nieto Y., Vredenburgh J. J., Shpall E. J., Bearman S. I., McSweeney P. A., Chao N., Rizzieri D., Gasparetto C., Matthes S., Baron A. E., Jones R. B. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clin. Cancer Res. 2004; 10: 7136–7143, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nieto Y., Xu X., Cagnoni P. J., Matthes S., Shpall E. J., Bearman S. I., Murphy J., Jones R. B. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. Clin. Cancer Res. 1999; 5: 747–751, [PUBMED], [INFOTRIEVE], [CSA]
- Niitsu Y., Takahashi Y., Ban N., Takayama T., Saito T., Katahira T., Umetsu Y., Nakajima T., Ohi M., Kuga T., Sakamaki S., Matsunaga T., Hirayama Y., Kuroda H., Homma H., Kato J., Kogawa K. A proof of glutathione S-transferase-pi-related multidrug resistance by transfer of antisense gene to cancer cells and sense gene to bone marrow stem cell. Chem. Biol. Interact. 1998; 111–112: 325–332, [CROSSREF], [CSA]
- Noe A. J., Malapetsa A., Panasci L. C. Transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in the human glioma cell line SK-MG-1 is mediated by an epinephrine-sensitive carrier system. Mol. Pharmacol. 1993; 44: 204–209, [PUBMED], [INFOTRIEVE], [CSA]
- Noe A. J., Malapetsa A., Panasci L. C. Altered cytotoxicity of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea in human glioma cell lines SK-MG-1 and SKI-1 correlates with differential transport kinetics. Cancer Res 1994; 54: 1491–1496, [PUBMED], [INFOTRIEVE], [CSA]
- Noe A. J., Marcantonio D., Barton J., Malapetsa A., Panasci L. C. Characterization of the catecholamine extraneuronal uptake2 carrier in human glioma cell lines SK-MG-1 and SKI-1 in relation to (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU) selective cytotoxicity. Biochem. Pharmacol. 1996; 51: 1639–1648, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Nooter K., Brutel de la Riviere G., Look M. P., van Wingerden K. E., Henzen-Logmans S. C., Scheper R. J., Flens M. J., Klijn J. G., Stoter G., Foekens J. A. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br. J. Cancer. 1997; 76: 486–493, [PUBMED], [INFOTRIEVE], [CSA]
- O’Connor P. M., Wassermann K., Sarang M., Magrath I., Bohr V. A., Kohn K. W. Relationship between DNA cross-links, cell cycle, and apoptosis in Burkitt’s lymphoma cell lines differing in sensitivity to nitrogen mustard. Cancer Res 1991; 51: 6550–6557, [CSA]
- O’Regan R. M., Von Roenn J. H., Carlson R. W., Malik U., Sparano J. A., Starabub V., Khan S., Jovanovic B., Morrow M., Gradishar W. J. Final results of a Phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer. Clin. Breast Cancer. 2005; 6: 163–168, [CSA]
- Orlando L., Curigliano G., Colleoni M., Fazio N., Nole F., Martinelli G., Cinieri S., Graffeo R., Peruzzotti G., Goldhirsch A. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res 2002; 22: 3057–3059, [PUBMED], [INFOTRIEVE], [CSA]
- Panasci L., Henderson D., Torres-Garcia S. J., Skalski V., Caplan S., Hutchinson M. Transport, metabolism, and DNA interaction of melphalan in lymphocytes from patients with chronic lymphocytic leukemia. Cancer Res 1988; 48: 1972–1976, [PUBMED], [INFOTRIEVE], [CSA]
- Panasci L. C., Marcantonio D., Noe A. J. SarCNU (2-chloroethyl-3-sarcosinamide-1-nitrosourea): a novel analogue of chloroethylnitrosourea that is transported by the catecholamine uptake2 carrier, which mediates increased cytotoxicity. Cancer Chemother. Pharmacol. 1996; 37: 505–508, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Papadimitriou C. A., Kouroussis C., Moulopoulos L. A., Vlahos G., Rodolakis A., Kiamouris C., Diakomanolis E., Gika D., Michalas S., Dimopoulos M. A. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer. Cancer 2001; 92: 1856–1863, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Parsons P. G., Lean J., Kable E. P., Favier D., Khoo S. K., Hurst T., Holmes R. S., Bellet A. J. Relationships between resistance to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines. Biochem. Pharmacol. 1990; 40: 2641–2649, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Patterson L. H., McKeown S. R., Robson T., Gallagher R., Raleigh S. M., Orr S. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Anticancer Drug Des 1999; 14: 473–486, [PUBMED], [INFOTRIEVE], [CSA]
- Patterson L. H., Murray G. I. Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 2002; 8: 1335–1347, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Patton S. E., Hall M. C., Ozen H. Bladder cancer. Curr. Opin. Oncol. 2002; 14: 265–272, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Paulusma C. C., Bosma P. J., Zaman G. J., Bakker C. T., Otter M., Scheffer G. L., Scheper R. J., Borst P., Oude Elferink R. P. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 1996; 271: 1126–1128, [PUBMED], [INFOTRIEVE], [CSA]
- Pavarana M., Nortilli R., Valcamonico F., Romito S., Zanoni T., Cetto G. Ifosfamide encephalopathy: a case report. Tumori 2005; 91: 197–200, [PUBMED], [INFOTRIEVE], [CSA]
- Payne G. S., Dzik-Jurasz A. S., Mancini L., Nutley B., Raynaud F., Leach M. O. Identification of biliary metabolites of ifosfamide using (31)P magnetic resonance spectroscopy and mass spectrometry. Cancer Chemother. Pharmacol. 2005; 56: 409–414, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Perez E. A. TAC–a new standard in adjuvant therapy for breast cancer?. N. Engl. J. Med. 2005; 352: 2346–2348, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Peters W. P., Stuart A., Klotman M., Gilbert C., Jones R. B., Shpall E. J., Gockerman J., Bast R. C., Jr., Moore J. O. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother. Pharmacol. 1989; 23: 377–383, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus 2004; 13: 366–371, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Petros W. P., Evans W. E. Pharmacogenomics in cancer therapy: is host genome variability important?. Trends Pharmacol. Sci. 2004; 25: 457–464, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pette M., Gold R., Pette D. F., Hartung H. P., Toyka K. V. Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes. A possible mechanism of its immunosuppressive action. Immunopharmacology 1995; 30: 59–69, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pico J. L., Rosti G., Kramar A., Wandt H., Koza V., Salvioni R., Theodore C., Lelli G., Siegert W., Horwich A., Marangolo M., Linkesch W., Pizzocaro G., Schmoll H. J., Bouzy J., Droz J. P., Biron P. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann. Oncol. 2005; 16: 1152–1159, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005; 23: 939–952, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Piura B., Rabinovich A. Doxorubicin and ifosfamide-mesna in advanced and recurrent uterine sarcomas. Eur. J. Gynaecol. Oncol. 2005; 26: 275–278, [PUBMED], [INFOTRIEVE], [CSA]
- Pocali B., De Simone M., Annunziata M., Palmieri S., D’Amico M. R., Copia C., Viola A., Mele G., Schiavone E. M., Ferrara F. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin’s lymphoma. Leuk. Lymphoma. 2004; 45: 1605–1609, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Praga C., Bergh J., Bliss J., Bonneterre J., Cesana B., Coombes R. C., Fargeot P., Folin A., Fumoleau P., Giuliani R., Kerbrat P., Hery M., Nilsson J., Onida F., Piccart M., Shepherd L., Therasse P., Wils J., Rogers D. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J. Clin. Oncol. 2005; 23: 4179–4191, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Prasad V. K., Corlett S. A., Abaasi K., Heney D., Lewis I., Chrystyn H. Ifosfamide enantiomers: pharmacokinetics in children. Cancer Chemother. Pharmacol. 1994; 34: 447–449, [PUBMED], [INFOTRIEVE], [CSA]
- Preiss R., Baumann F., Stefanovic D., Niemeyer U., Ponisch W., Niederwieser D. Investigations on the pharmacokinetics of trofosfamide and its metabolites-first report of 4-hydroxy-trofosfamide kinetics in humans. Cancer Chemother. Pharmacol. 2004; 53: 496–502, [PUBMED], [INFOTRIEVE], [CSA]
- Preuss I., Thust R., Kaina B. Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs. Int. J. Cancer. 1996; 65: 506–512, [PUBMED], [INFOTRIEVE], [CSA]
- Pritchard K. I., Paterson A. H., Fine S., Paul N. A., Zee B., Shepherd L. E., Abu-Zahra H., Ragaz J., Knowling M., Levine M. N., Verma S., Perrault D., Walde P. L., Bramwell V. H., Poljicak M., Boyd N., Warr D., Norris B. D., Bowman D., Armitage G. R., Weizel H., Buckman R. A. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group. J. Clin. Oncol. 1997; 15: 2302–2311, [PUBMED], [INFOTRIEVE], [CSA]
- Qiu R., Kalhorn T. F., Slattery J. T. ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat. J. Pharmacol. Exp. Ther. 2004; 308: 1204–1212, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Quash G., Fournet G., Chantepie J., Gore J., Ardiet C., Ardail D., Michal Y., Reichert U. Novel competitive irreversible inhibitors of aldehyde dehydrogenase (ALDH1): restoration of chemosensitivity of L1210 cells overexpressing ALDH1 and induction of apoptosis in BAF(3) cells overexpressing bcl(2). Biochem. Pharmacol. 2002; 64: 1279–1292, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Radin A. I., Zhoa X. L., Woo T. H., Colvin O. M., Hilton J. Structure and expression of the cytosolic aldehyde dehydrogenase gene in cyclophosphamide-resistant murine leukemia L1210 cells. Biochem. Pharmacol. 1991; 42: 1933–1939, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rae J. M., Soukhova N. V., Flockhart D. A., Desta Z. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab. Dispos. 2002; 30: 525–530, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ramu K., Fraiser L. H., Mamiya B., Ahmed T., Kehrer J. P. Acrolein mercapturates: synthesis, characterization, and assessment of their role in the bladder toxicity of cyclophosphamide. Chem. Res. Toxicol. 1995; 8: 515–524, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ramu K., Perry C. S., Ahmed T., Pakenham G., Kehrer J. P. Studies on the basis for the toxicity of acrolein mercapturates. Toxicol. Appl. Pharmacol. 1996; 140: 487–498, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rao R., Shammo J. M., Enschede S. H., Porter C., Adler S. S., Venugopal P., Gregory S. A. The combination of fludarabine, cyclophosphamide, and granulocyte-macrophage colony-stimulating factor in the treatment of patients with relapsed chronic lymphocytic leukemia and low-grade non-Hodgkin’s lymphoma. Clin. Lymphoma. 2005; 6: 26–30, [PUBMED], [INFOTRIEVE], [CSA]
- Redwood W. R., Colvin M. Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res 1980; 40: 1144–1149, [PUBMED], [INFOTRIEVE], [CSA]
- Reichardt P., Pink D., Tilgner J., Kretzschmar A., Thuss-Patience P. C., Dorken B. Oral trofosfamide: an active and well-tolerated maintenance therapy for adult patients with advanced bone and soft tissue sarcomas. Results of a retrospective analysis. Onkologie 2002; 25: 541–546, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rekha G. K., Devaraj V. R., Sreerama L., Lee M. J., Nagasawa H. T., Sladek N. E. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by chlorpropamide analogues. Biochem. Pharmacol. 1998; 55: 465–474, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rekha G. K., Sladek N. E. Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol. Adv. Exp. Med. Biol. 1997; 414: 133–146, [PUBMED], [INFOTRIEVE], [CSA]
- Rekha G. K., Sreerama L., Sladek N. E. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem. Pharmacol. 1994; 48: 1943–1952, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ren S., Kalhorn T. F., McDonald G. B., Anasetti C., Appelbaum F. R., Slattery J. T. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin. Pharmacol. Ther. 1998; 64: 289–301, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ren S., Yang J. S., Kalhorn T. F., Slattery J. T. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997; 57: 4229–4235, [PUBMED], [INFOTRIEVE], [CSA]
- Richardson M. E., Siemann D. W. DNA damage in cyclophosphamide-resistant tumor cells: the role of glutathione. Cancer Res 1995; 55: 1691–1695, [PUBMED], [INFOTRIEVE], [CSA]
- Riddick D. S., Lee C., Ramji S., Chinje E. C., Cowen R. L., Williams K. J., Patterson A. V., Stratford I. J., Morrow C. S., Townsend A. J., Jounaidi Y., Chen C. S., Su T., Lu H., Schwartz P. S., Waxman D. J. Cancer chemotherapy and drug metabolism. Drug Metab. Dispos. 2005; 33: 1083–1096, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rizzo W. B., Carney G., Lin Z. The molecular basis of Sjogren-Larsson syndrome: mutation analysis of the fatty aldehyde dehydrogenase gene. Am. J. Hum. Genet. 1999; 65: 1547–1560, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rodin S. M., Johnson B. F. Pharmacokinetic interactions with digoxin. Clin. Pharmacokinet. 1988; 15: 227–244, [PUBMED], [INFOTRIEVE], [CSA]
- Rodrigues A. D., Rushmore T. H. Cytochrome P450 pharmacogenetics in drug development: In vitro studies and clinical consequences. Curr. Drug. Metab. 2002; 3: 289–309, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rogowska E., Wozniak W. [Nephrotoxicity of ifosfamide with special reference to Fanconi Syndrome]. Med. Wieku. Rozwoj. 2004; 8: 289–295, [PUBMED], [INFOTRIEVE], [CSA]
- Rooseboom M., Commandeur J. N., Vermeulen N. P. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol. Rev. 2004; 56: 53–102, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rousseau A., Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam. Clin. Pharmacol. 2002; 16: 253–262, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Roy P., Tretyakov O., Wright J., Waxman D. J. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer. Drug. Metab. Dispos. 1999a; 27: 1309–1318, [PUBMED], [INFOTRIEVE], [CSA]
- Roy P., Yu L. J., Crespi C. L., Waxman D. J. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug. Metab. Dispos. 1999b; 27: 655–666, [PUBMED], [INFOTRIEVE], [CSA]
- Rozados V. R., Sanchez A. M., Gervasoni S. I., Berra H. H., Matar P., Graciela Scharovsky O. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. Ann. Oncol. 2004; 15: 1543–1550, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rudek M. A., Sparreboom A., Garrett-Mayer E. S., Armstrong D. K., Wolff A. C., Verweij J., Baker S. D. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur. J. Cancer. 2004; 40: 1170–1178, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rudlowski C., Moser M., Becker A. J., Rath W., Buttner R., Schroder W., Schurmann A. GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer. Oncology 2004; 66: 404–410, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Russo J. E., Hilton J. Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res 1988; 48: 2963–2968, [PUBMED], [INFOTRIEVE], [CSA]
- Ruzicka J. A., Ruenitz P. C. Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosfamide in the rat. Drug. Metab. Dispos. 1992; 20: 770–772, [PUBMED], [INFOTRIEVE], [CSA]
- Sahovic E. A., Colvin M., Hilton J., Ogawa M. Role for aldehyde dehydrogenase in survival of progenitors for murine blast cell colonies after treatment with 4-hydroperoxycyclophosphamide in vitro. Cancer Res 1988; 48: 1223–1226, [PUBMED], [INFOTRIEVE], [CSA]
- Scambia G., Panici P. B., Pierelli L., Baiocchi G., Rumi C., Menichella G., Foddai M. L., Serafini R., Arno E., Bonanno G. Immunological reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation for advanced ovarian cancer. Eur. J. Cancer. 1993; 29A: 1518–1522, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schmidt R., Baumann F., Knupfer H., Brauckhoff M., Horn L. C., Schonfelder M., Kohler U., Preiss R. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br. J. Cancer. 2004; 90: 911–916, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schuler U., Ehninger G., Wagner T. Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites. Cancer Chemother. Pharmacol. 1987; 20: 248–252, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schwartz P. S., Chen C. S., Waxman D. J. Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. Cancer Res 2002; 62: 6928–6937, [PUBMED], [INFOTRIEVE], [CSA]
- Schwartz P. S., Chen C. S., Waxman D. J. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Cancer Gene Ther 2003; 10: 571–582, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Schwartz P. S., Waxman D. J. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol. Pharmacol. 2001; 60: 1268–1279, [PUBMED], [INFOTRIEVE], [CSA]
- Seker H., Bertram B., Burkle A., Kaina B., Pohl J., Koepsell H., Wiesser M. Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent. Br. J. Cancer. 2000; 82: 629–634, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Seker H., Bertram B., Wieler M. Possible role of the cytosolic-glucosidase in the metabolism of saccharide-coupled platinum and ifosfamide mustard in tumour cells. 10th Mediterranean Congress of Chemotherapy, B. Berkarda. Monduzzi Editore. 1996; 381–385
- Sener G., Sehirli O., Yegen B. C., Cetinel S., Gedik N., Sakarcan A. Melatonin attenuates ifosfamide-induced Fanconi syndrome in rats. J. Pineal. Res. 2004; 37: 17–25, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Seo J. H., Whang Y. M., Kim B. S., Choi C. W., Shin S. W., Kim Y. H., Kim J. S., Goo B. H. A phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma. Cancer 2002; 94: 1925–1930, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J. Pharmacol. Exp. Ther. 1994; 270: 414–423, [PUBMED], [INFOTRIEVE], [CSA]
- Siebert D. Comparison of the genetic activity of cyclophosphamide, ifosfamide and trofosfamide in host-mediated assays with the gene conversion system of yeast. Z. Krebsforsch Klin. Onkol. Cancer Res. Clin. Oncol. 1974; 81: 261–267, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Siena S., Castro-Malaspina H., Gulati S. C., Lu L., Colvin M. O., Clarkson B. D., O’Reilly R. J., Moore M. A. Effects of in vitro purging with 4-hydroperoxycyclophosphamide on the hematopoietic and microenvironmental elements of human bone marrow. Blood 1985; 65: 655–662, [PUBMED], [INFOTRIEVE], [CSA]
- Sillen A., Alderborn A., Pigg M., Jagell S., Wadelius C. Detailed genetic and physical mapping in the Sjogren-Larsson syndrome gene region in 17p11.2. Hereditas 1998; 128: 245–250, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Simbre V. C., Duffy S. A., Dadlani G. H., Miller T. L., Lipshultz S. E. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr. Drugs. 2005; 7: 187–202, [PUBMED], [INFOTRIEVE], [CSA]
- Simoes-Wust A. P., Schurpf T., Hall J., Stahel R. A., Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Br. Cancer Res. Treat. 2002; 76: 157–166, [CROSSREF], [CSA]
- Skalski V., Feindel W., Panasci L. C. Transport of amino acid amide sarcosinamide and sarcosinamide chloroethylnitrosourea in human glioma SK-MG-1 cells. Cancer Res 1990; 50: 3062–3066, [PUBMED], [INFOTRIEVE], [CSA]
- Skinner R., Sharkey I. M., Pearson A. D., Craft A. W. Ifosfamide, mesna, and nephrotoxicity in children. J. Clin. Oncol. 1993; 11: 173–190, [PUBMED], [INFOTRIEVE], [CSA]
- Sladek N. E. Metabolism of oxazaphosphorines. Pharmacol. Ther. 1988; 37: 301–355, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sladek N. E. Leukemic cell insensitivity to cyclophosphamide and other oxazaphosphorines mediated by aldehyde dehydrogenase(s). Cancer Treat. Res. 2002; 112: 161–175, [PUBMED], [INFOTRIEVE], [CSA]
- Sladek N. E., Dockham P. A., Lee M. O. Human and mouse hepatic aldehyde dehydrogenases important in the biotransformation of cyclophosphamide and the retinoids. Adv. Exp. Med. Biol. 1991; 284: 97–104, [PUBMED], [INFOTRIEVE], [CSA]
- Sladek N. E., Doeden D., Powers J. F., Krivit W. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat. Rep. 1984; 68: 1247–1254, [PUBMED], [INFOTRIEVE], [CSA]
- Sladek N. E., Kollander R., Sreerama L., Kiang D. T. Cellular levels of aldehyde dehydrogenases (ALDH1A1 and ALDH3A1) as predictors of therapeutic responses to cyclophosphamide-based chemotherapy of breast cancer: a retrospective study. Rational individualization of oxazaphosphorine-based cancer chemotherapeutic regimens. Cancer Chemother. Pharmacol. 2002; 49: 309–321, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sladek N. E., Landkamer G. J. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Cancer Res 1985; 45: 1549–1555, [PUBMED], [INFOTRIEVE], [CSA]
- Slattery J. T., Kalhorn T. F., McDonald G. B., Lambert K., Buckner C. D., Bensinger W. I., Anasetti C., Appelbaum F. R. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J. Clin. Oncol. 1996; 14: 1484–1494, [PUBMED], [INFOTRIEVE], [CSA]
- Smith I. E., Perren T. J., Ashley S. A., Woodiwiss J., Forgeson G. V., Yarnold J. R., Ford H. T. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. J. Clin. Oncol. 1990; 8: 899–905, [PUBMED], [INFOTRIEVE], [CSA]
- Smith R. E. Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin. Breast Cancer. 2003; 4: 273–279, [PUBMED], [INFOTRIEVE], [CSA]
- Smith T. A. Facilitative glucose transporter expression in human cancer tissue. Br. J. Biomed. Sci. 1999; 56: 285–292, [PUBMED], [INFOTRIEVE], [CSA]
- Solomon S. R., Mielke S., Savani B. N., Montero A., Wisch L., Childs R., Hensel N., Schindler J., Ghetie V., Leitman S. F., Mai T., Carter C. S., Kurlander R., Read E. J., Vitetta E. S., Barrett A. J. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 2005; 106: 1123–1129, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Solus J. F., Arietta B. J., Harris J. R., Sexton D. P., Steward J. Q., McMunn C., Ihrie P., Mehall J. M., Edwards T. L., Dawson E. P. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 2004; 5: 895–931, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Son B. H., Ahn S. H., Ko C. D., Ka I. W., Gong G. Y., Kim J. C. Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. Breast J 2004; 10: 20–26, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sood C., O’Brien P. J. Molecular mechanisms of chloroacetaldehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem. Pharmacol. 1993; 46: 1621–1626, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sophos N. A., Pappa A., Ziegler T. L., Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2000 update. Chem. Biol. Interact. 2001; 130–132: 323–337, [CROSSREF], [CSA]
- Sophos N. A., Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2002 update. Chem. Biol. Interact. 2003; 143–144: 5–22, [CROSSREF], [CSA]
- Sorio R., Lombardi D., Spazzapan S., La Mura N., Tabaro G., Veronesi A. Ifosfamide in advanced/disseminated breast cancer. Oncology 2003; 65(Suppl 2)55–58, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Souliotis V. L., Dimopoulos M. A., Sfikakis P. P. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin. Cancer Res. 2003; 9: 4465–4474, [PUBMED], [INFOTRIEVE], [CSA]
- Spengler S. J., Singer B. Formation of interstrand cross-links in chloroacetaldehyde-treated DNA demonstrated by ethidium bromide fluorescence. Cancer Res 1988; 48: 4804–4806, [PUBMED], [INFOTRIEVE], [CSA]
- Sportes C., McCarthy N. J., Hakim F., Steinberg S. M., Liewehr D. J., Weng D., Kummar S., Gea-Banacloche J., Chow C. K., Dean R. M., Castro K. M., Marchigiani D., Bishop M. R., Fowler D. H., Gress R. E. Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients. Biol. Blood Marrow Transplant. 2005; 11: 472–483, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Springate J., Zamlauski-Tucker M. J., Lu H., Chan K. K. Renal clearance of ifosfamide. Drug Metab. Dispos. 1997; 25: 1081–1082, [PUBMED], [INFOTRIEVE], [CSA]
- Springate J. E. Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. J. Appl. Toxicol. 1997; 17: 75–79, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Springer J. B., Colvin M. E., Colvin O. M., Ludeman S. M. Isophosphoramide mustard and its mechanism of bisalkylation. J. Org. Chem. 1998; 63: 7218–7222, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sreerama L., Rekha G. K., Sladek N. E. Phenolic antioxidant-induced overexpression of class-3 aldehyde dehydrogenase and oxazaphosphorine-specific resistance. Biochem. Pharmacol. 1995; 49: 669–675, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sreerama L., Sladek N. E. Identification and characterization of a novel class 3 aldehyde dehydrogenase overexpressed in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Biochem. Pharmacol. 1993; 45: 2487–2505, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sreerama L., Sladek N. E. Identification of the class-3 aldehyde dehydrogenases present in human MCF-7/0 breast adenocarcinoma cells and normal human breast tissue. Biochem. Pharmacol. 1994; 48: 617–620, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sreerama L., Sladek N. E. Cellular levels of class 1 and class 3 aldehyde dehydrogenases and certain other drug-metabolizing enzymes in human breast malignancies. Clin. Cancer Res. 1997; 3: 1901–1914, [PUBMED], [INFOTRIEVE], [CSA]
- Srivastava A., Murari M., Datta N. R. Early occurrence of acute myeloid leukemia following adjuvant radiotherapy and higher cumulative dose of cyclophosphamide in carcinoma breast. Indian J. Cancer. 2004; 41: 178–180, [PUBMED], [INFOTRIEVE], [CSA]
- Stephens R. J., Girling D. J., Hopwood P., Thatcher N. A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1–3, N2, M0 non-small cell lung cancer. Lung Cancer. 2005; 49, [CROSSREF], [CSA]
- Stewart D. A., Paterson A. H., Ruether J. D., Russell J., Craighead P., Smylie M., Mackey J. High-dose mitoxantrone-vinblastine-cyclophosphamide and autologous stem cell transplantation for stage III breast cancer: final results of a prospective multicentre study. Ann. Oncol. 2005; 16, [CROSSREF], [CSA]
- Stewart D. J., Morgan L. R., Jr., Verma S., Maroun J. A., Thibault M. Pharmacology, relative bioavailability, and toxicity of three different oral cyclophosphamide preparations in a randomized, cross-over study. Invest. New Drugs. 1995; 13: 99–107, [PUBMED], [INFOTRIEVE], [CSA]
- Stiff P. J., Shpall E. J., Liu P. Y., Wilczynski S. P., Callander N. S., Scudder S. A., Jazieh A. R., Samlowski W., McCoy J., Alberts D. S. Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecol. Oncol. 2004; 94: 98–106, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Stresser D. M., Kupfer D. Monospecific antipeptide antibody to cytochrome P-450 2B6. Drug Metab. Dispos. 1999; 27: 517–525, [PUBMED], [INFOTRIEVE], [CSA]
- Struck R. F., Dykes D. J., Corbett T. H., Suling W. J., Trader M. W. Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide. Br. J. Cancer. 1983; 47: 15–26, [PUBMED], [INFOTRIEVE], [CSA]
- Struck R. F., Kirk M. C., Witt M. H., Laster W. R., Jr. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed. Mass. Spectrom. 1975; 2: 46–52, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Strumberg D., Harstrick A., Klaassen U., Muller C., Eberhardt W., Korn M. W., Wilke H., Seeber S. Phase II trial of continuous oral trofosfamide in patients with advanced colorectal cancer refractory to 5-fluorouracil. Anticancer Drugs 1997; 8: 293–295, [PUBMED], [INFOTRIEVE], [CSA]
- Studzian K., Kinas R., Ciesielska E., Szmigiero L. Effects of alkylating metabolites of ifosfamide and its bromo analogues on DNA of HeLa cells. Biochem. Pharmacol. 1992; 43: 937–943, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Suami T., Kato T., Takino H., Hisamatsu T. (2-Chloroethyl)nitrosourea congeners of amino acid amides. J. Med. Chem. 1982; 25: 829–832, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sun X. M., MacFarlane M., Zhuang J., Wolf B. B., Green D. R., Cohen G. M. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J. Biol. Chem. 1999; 274: 5053–5060, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Sundstrom S., Bremnes R. M., Kaasa S., Aasebo U., Aamdal S. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 2005; 48: 251–261, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Suzuki H., Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 2002; 54: 1311–1331, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Szumilas P., Barcew K., Baskiewicz-Masiuk M., Wiszniewska B., Ratajczak M. Z., Machalinski B. Effect of stem cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor on morphology of haematopoietic organs in mice. Cell Prolif 2005; 38: 47–61, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Takada K., Arefayene M., Desta Z., Yarboro C. H., Boumpas D. T., Balow J. E., Flockhart D. A., Illei G. G. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50: 2202–2210, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Takebe N., Zhao S. C., Adhikari D., Mineishi S., Sadelain M., Hilton J., Colvin M., Banerjee D., Bertino J. R. Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. Mol. Ther. 2001; 3: 88–96, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tanner B., Hengstler J. G., Dietrich B., Henrich M., Steinberg P., Weikel W., Meinert R., Kaina B., Oesch F., Knapstein P. G. Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol. Oncol. 1997; 65: 54–62, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tassinari D., Genestreti G., Pasquini E., Papi M., Fantini M., Tamburini E., Fochessati F., Poggi B., Imola M., Mianulli A. M., Fattori P. P., Lazzari-Agli L., Ioli G., Sartori S., Ravaioli A. Efficacy of two different platinum- or anthracycline-containing chemotherapy regimens for the treatment of small cell lung cancer. J. Chemother. 2005; 17: 228–236, [PUBMED], [INFOTRIEVE], [CSA]
- Teicher B. A., Cucchi C. A., Lee J. B., Flatow J. L., Rosowsky A., Frei E., 3rd. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Cancer Res 1986; 46: 4379–4383, [PUBMED], [INFOTRIEVE], [CSA]
- Teicher B. A., Frei E., 3rd. Development of alkylating agent-resistant human tumor cell lines. Cancer Chemother. Pharmacol. 1988; 21: 292–298, [PUBMED], [INFOTRIEVE], [CSA]
- Thomson B., Park J. R., Felgenhauer J., Meshinchi S., Holcenberg J., Geyer J. R., Avramis V., Douglas J. G., Loken M. R., Hawkins D. S. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Pediatr. Blood Cancer. 2004; 43: 571–579, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thummel K. E., Shen D. D., Podoll T. D., Kunze K. L., Trager W. F., Hartwell P. S., Raisys V. A., Marsh C. L., McVicar J. P., Barr D. M., Perkins J. D. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 1994; 271: 549–556, [PUBMED], [INFOTRIEVE], [CSA]
- Tian Q., Zhang J., Chan E., Duan W., Zhou S. F. Multidrug resistance proteins (MRPs) and implication in drug development. Drug Dev. Res. 2005a; 51: 1–18, [CROSSREF], [CSA]
- Tian Q., Zhang J., Tan T. M., Chan E., Duan W., Chan S. Y., Boelsterli U. A., Ho P. C., Yang H., Bian J. S., Huang M., Zhu Y. Z., Xiong W. P., Li X. T., Zhou S. F. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res. 2005b, in press[CSA]
- Toh S., Wada M., Uchiumi T., Inokuchi A., Makino Y., Horie Y., Adachi Y., Sakisaka S., Kuwano M. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Human Genet. 1999; 64: 739–746, [CSA]
- Toma S., Palumbo R., Comandone A., Oliva C., Vincenti M., Bumma C., Rosso R. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study. Ann. Oncol. 1995; 6: 193–196, [PUBMED], [INFOTRIEVE], [CSA]
- Trappe R. U., Riess H., Lippek F., Plotkin M., Schumacher V., Royer-Pokora B., Hildebrandt B., Zuber J., Mapara M. Y., Oertel S., Dorken B. Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms’ tumor and a novel alteration in intron 1 of the WT1 gene. J. Pediatr. Hematol. Oncol. 2004; 26: 820–823, [PUBMED], [INFOTRIEVE], [CSA]
- Tsukamoto N., Chen J., Yoshida A. Enhanced expressions of glucose-6-phosphate dehydrogenase and cytosolic aldehyde dehydrogenase and elevation of reduced glutathione level in cyclophosphamide-resistant human leukemia cells. Blood Cells Mol. Dis. 1998; 24: 231–238, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Uckun F. M., Chandan-Langlie M., Dockham P. A., Aeppli D., Sladek N. E. Sensitivity of primary clonogenic blasts from acute lymphoblastic leukemia patients to an activated cyclophosphamide, viz., mafosfamide. Leuk. Lymphoma. 1994; 13: 417–428, [PUBMED], [INFOTRIEVE], [CSA]
- Usui N., Yano S., Asai O., Dobashi N., Osawa H., Takei Y., Sugiyama K., Takahara S., Otubo H., Saito T., Okawa Y., Hagino T., Kaito K., Kobayashi M. Long-term follow-up high-dose chemotherapy (drug-only program) followed by autologous stem cell transplantation for aggressive non-hodgkin’s lymphomas. Clin. Lymphoma. 2005; 6: 31–36, [PUBMED], [INFOTRIEVE], [CSA]
- van den Bent M. J., Grisold W., Frappaz D., Stupp R., Desir J. P., Lesimple T., Dittrich C., de Jonge M. J., Brandes A., Frenay M., Carpentier A. F., Chollet P., Oliveira J., Baron B., Lacombe D., Schuessler M., Fumoleau P. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann. Oncol. 2003; 14: 1732–1734, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- van Maanen M. J., Huitema A. D., Rodenhuis S., Beijnen J. H. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin. Anticancer Drugs 2001; 12: 519–524, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vanhoefer U., Schleucher N., Klaassen U., Seeber S., Harstrick A. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic. Semin. Oncol. 2000; 27: 8–13, [PUBMED], [INFOTRIEVE], [CSA]
- Vasiliou V. Aldehyde dehydrogenase genes. Adv. Exp. Med. Biol. 1997; 414: 595–600, [PUBMED], [INFOTRIEVE], [CSA]
- Vasiliou V., Pappa A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. Pharmacology 2000; 61: 192–198, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vasiliou V., Pappa A., Estey T. Role of human aldehyde dehydrogenases in endobiotic and xenobiotic metabolism. Drug Metab. Rev. 2004; 36: 279–299, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vasoo S., Hughes G. R. Theory, targets and therapy in systemic lupus erythematosus. Lupus 2005; 14: 181–188, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Veldhuis G. J., Willemse P. H., Beijnen J. H., Boonstra H., Piersma H., van der Graaf W. T., de Vries E. G. Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. Br. J. Cancer. 1997; 75: 703–709, [PUBMED], [INFOTRIEVE], [CSA]
- Verburg R. J., Sont J. K., van Laar J. M. Reduction of joint damage in severe rheumatoid arthritis by high-dose chemotherapy and autologous stem cell transplantation. Arthritis Rheum 2005; 52: 421–424, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vester U., Kranz B., Zimmermann S., Buscher R., Hoyer P. F. The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1. Pediatr. Nephrol. 2005; 20: 478–481, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Veyhl M., Wagner K., Volk C., Gorboulev V., Baumgarten K., Weber W. M., Schaper M., Bertram B., Wiessler M., Koepsell H. Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. Proc. Natl. Acad. Sci. USA. 1998; 95: 2914–2919, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vitolo U., Liberati A. M., Cabras M. G., Federico M., Angelucci E., Baldini L., Boccomini C., Brugiatelli M., Calvi R., Ciccone G., Genua A., Deliliers G. L., Levis A., Parvis G., Pavone E., Salvi F., Sborgia M., Gallo E. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an “Intergruppo Italiano Linfomi” randomized trial. Haematologica 2005; 90: 793–801, [PUBMED], [INFOTRIEVE], [CSA]
- Voelcker G., Bielicki L., Hohorst H. J. Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation. J. Cancer Res. Clin. Oncol. 1997; 123: 623–631, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Voelcker G., Hohorst H. J. Structure/activity studies with thiazolidinyl- and perhydrothiazinylphosphamide ester. J. Cancer Res. Clin. Oncol. 1998; 124: 297–300, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- von Eitzen U., Meier-Tackmann D., Agarwal D. P., Goedde H. W. Detoxification of cyclophosphamide by human aldehyde dehydrogenase isozymes. Cancer Lett 1994; 76: 45–49, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vyas S., Hidalgo G., Baqi N., Von Gizyki H., Singh A. Outcome in African-American children of neuropsychiatric lupus and lupus nephritis. Pediatr. Nephrol. 2002; 17: 45–49, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wagner T. Ifosfamide clinical pharmacokinetics. Clin. Pharmacokinet. 1994; 26: 439–456, [PUBMED], [INFOTRIEVE], [CSA]
- Wagner T., Drings P. Pharmacokinetics and bioavailability of oral ifosfamide. Arzneimittelforschung 1986; 36: 878–880, [PUBMED], [INFOTRIEVE], [CSA]
- Wagner T., Fenneberg K. Bioavailability of cyclophosphamide from oral formulations. Eur. J. Clin. Pharmacol. 1984a; 26: 269–270, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wagner T., Fenneberg K. Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations. Arzneimittelforschung 1984b; 34: 313–316, [PUBMED], [INFOTRIEVE], [CSA]
- Wainer I. W., Ducharme J., Granvil C. P. The N-dechloroethylation of ifosfamide: using stereochemistry to obtain an accurate picture of a clinically relevant metabolic pathway. Cancer Chemother. Pharmacol. 1996; 37: 332–336, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wainer I. W., Granvil C. P., Wang T., Batist G. Efficacy and toxicity of ifosfamide stereoisomers in an in vivo rat mammary carcinoma model. Cancer Res 1994; 54: 4393–4397, [PUBMED], [INFOTRIEVE], [CSA]
- Wakusawa S., Machida I., Suzuki S., Hayashi H., Yano M., Yoshioka K. Identification of a novel 2026G→C mutation of the MRP2 gene in a Japanese patient with Dubin-Johnson syndrome. J. Hum. Genet. 2003; 48: 425–429, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Walker D., Flinois J. P., Monkman S. C., Beloc C., Boddy A. V., Cholerton S., Daly A. K., Lind M. J., Pearson A. D., Beaune P. H. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem. Pharmacol. 1994; 47: 1157–1163, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wang H., LeCluyse E. L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 2003; 42: 1331–1357, [PUBMED], [INFOTRIEVE], [CSA]
- Watkins P. B. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994; 4: 171–184, [PUBMED], [INFOTRIEVE], [CSA]
- Watters J. W., Kloss E. F., Link D. C., Graubert T. A., McLeod H. L. A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J. Appl. Physiol. 2003; 95: 1352–1360, [PUBMED], [INFOTRIEVE], [CSA]
- Waxman D. J., Schwartz P. S. Harnessing apoptosis for improved anticancer gene therapy. Cancer Res 2003; 63: 8563–8572, [PUBMED], [INFOTRIEVE], [CSA]
- Wierecky J., Kollmannsberger C., Boehlke I., Kuczyk M., Schleicher J., Schleucher N., Metzner B., Kanz L., Hartmann J. T., Bokemeyer C. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J. Cancer Res. Clin. Oncol. 2005; 131: 255–260, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wilde S., Jetter A., Zaigier M., Rietbrock S., Menzel H., Sieber M., Tesch H., Hempel G., Busse D., Schwab M., Reif S., Jaehde U., Diehl V., Fuhr U. Population pharmacokinetics of cyclophosphamide, doxorubicin and etoposide in 30 patients with BEACOPP chemotherapy. Int. J. Clin. Pharmacol. Ther. 2002; 40: 586–588, [PUBMED], [INFOTRIEVE], [CSA]
- Williams M. L., Wainer I. W. Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question. Curr. Pharm. Des. 1999; 5: 665–672, [PUBMED], [INFOTRIEVE], [CSA]
- Williams M. L., Wainer I. W., Embree L., Barnett M., Granvil C. L., Ducharme M. P. Enantioselective induction of cyclophosphamide metabolism by phenytoin. Chirality 1999; 11: 569–574, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Willits I., Price L., Parry A., Tilby M. J., Ford D., Cholerton S., Pearson A. D., Boddy A. V. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br. J. Cancer. 2005; 92: 1626–1635, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Willson T. M., Kliewer S. A. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 2002; 1: 259–266, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wilmer J. L., Colvin O. M., Bloom S. E. Cytogenetic mechanisms in the selective toxicity of cyclophosphamide analogs and metabolites towards avian embryonic B lymphocytes in vivo. Mutat. Res. 1992; 268: 115–130, [PUBMED], [INFOTRIEVE], [CSA]
- Wilmer J. L., Erexson G. L., Kligerman A. D. Effect of acrolein on phosphoramide mustard-induced sister chromatid exchanges in cultured human lymphocytes. Cancer Res 1990; 50: 4635–4638, [PUBMED], [INFOTRIEVE], [CSA]
- Wilson W. R., Pullen S. M., Hogg A., Hobbs S. M., Pruijn F. B., Hicks K. O. In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. Methods Mol. Med. 2004; 90: 403–431, [PUBMED], [INFOTRIEVE], [CSA]
- Woodland C., Ito S., Granvil C. P., Wainer I. W., Klein J., Koren G. Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 2000; 68: 109–117, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wormhoudt L. W., Commandeur J. N. M., Vermeulen N. P. E. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-Transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit. Rev. Toxicol. 1999; 29: 59–124, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wroczynski P., Laskowska A., Wierzchowski J., Szubert A., Polanski J., Slowiaczek M. Aldehyde dehydrogenase isoenzymes in tumours–assay with possible prognostic value for oxazaphosphorine chemotherapy. Acta Biochim. Pol. 1998; 45: 33–40, [PUBMED], [INFOTRIEVE], [CSA]
- Xie H., Afsharian P., Terelius Y., Mirghani R. A., Yasar U., Hagbjork A. L., Lundgren S., Hu Y., Rane A., Hassan M. Cyclophosphamide induces mRNA, protein and enzyme activity of cytochrome P450 in rat. Xenobiotica 2005; 35: 239–251, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Xie H. J., Lundgren S., Broberg U., Finnstrom N., Rane A., Hassan M. Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur. J. Pharmacol. 2002; 449: 197–205, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yalcin B., Pamir A., Buyukcelik A., Utkan G., Akbulut H., Demirkazik A., Icli F. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. Exp. Oncol. 2004; 26: 320–325, [PUBMED], [INFOTRIEVE], [CSA]
- Yamauchi T., Keating M. J., Plunkett W. UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol. Cancer Ther. 2002; 1: 287–294, [PUBMED], [INFOTRIEVE], [CSA]
- Yamauchi T., Nowak B. J., Keating M. J., Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res. 2001; 7: 3580–3589, [PUBMED], [INFOTRIEVE], [CSA]
- Yang Q. F., Sakurai T., Yoshimura G., Shan L., Suzuma T., Tamaki T., Umemura T., Kokawa Y., Nakamura Y., Nakamura M., Tang W., Utsunomiya H., Mori I., Kakudo K. Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma. Br. Cancer Res. Treat. 2000; 61: 211–216, [CSA]
- Ye Z., Song H. Glutathione s-transferase polymorphisms (GSTM1, GSTP1 and GSTT1) and the risk of acute leukaemia: A systematic review and meta-analysis. Eur. J. Cancer. 2005; 41: 980–989, [PUBMED], [INFOTRIEVE], [CSA]
- Yoshida A. Molecular genetics of human aldehyde dehydrogenase. Pharmacogenetics 1992; 2: 139–147, [PUBMED], [INFOTRIEVE], [CSA]
- Yoshida A., Dave V., Han H., Scanlon K. J. Enhanced transcription of the cytosolic ALDH gene in cyclophosphamide resistant human carcinoma cells. Adv. Exp. Med. Biol. 1993; 328: 63–72, [PUBMED], [INFOTRIEVE], [CSA]
- Yoshida A., Hsu L. C., Dave V. Retinal oxidation activity and biological role of human cytosolic aldehyde dehydrogenase. Enzyme 1992; 46: 239–244, [PUBMED], [INFOTRIEVE], [CSA]
- Yoshida A., Rzhetsky A., Hsu L. C., Chang C. Human aldehyde dehydrogenase gene family. Eur. J. Biochem. 1998; 251: 549–557, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Younes M., Juarez D., Lechago L. V., Lerner S. P. Glut 1 expression in transitional cell carcinoma of the urinary bladder is associated with poor patient survival. Anticancer Res 2001; 21: 575–578, [PUBMED], [INFOTRIEVE], [CSA]
- Yu L., Waxman D. J. Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab. Dispos. 1996; 24: 1254–1262, [PUBMED], [INFOTRIEVE], [CSA]
- Yu L. J., Drewes P., Gustafsson K., Brain E. G., Hecht J. E., Waxman D. J. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. J. Pharmacol. Exp. Ther. 1999; 288: 928–937, [PUBMED], [INFOTRIEVE], [CSA]
- Yu L. J., Matias J., Scudiero D. A., Hite K. M., Monks A., Sausville E. A., Waxman D. J. P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab. Dispos. 2001; 29: 304–312, [PUBMED], [INFOTRIEVE], [CSA]
- Yule S. M., Boddy A. V., Cole M., Price L., Wyllie R., Tasso M. J., Pearson A. D., Idle J. R. Cyclophosphamide metabolism in children. Cancer Res 1995; 55: 803–809, [PUBMED], [INFOTRIEVE], [CSA]
- Yule S. M., Boddy A. V., Cole M., Price L., Wyllie R., Tasso M. J., Pearson A. D., Idle J. R. Cyclophosphamide pharmacokinetics in children. Br. J. Clin. Pharmacol. 1996; 41: 13–19, [PUBMED], [INFOTRIEVE], [CSA]
- Yule S. M., Price L., Cole M., Pearson A. D., Boddy A. V. Cyclophosphamide metabolism in children with Fanconi’s anaemia. Bone Marrow Transplant 1999a; 24: 123–128, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yule S. M., Price L., Cole M., Pearson A. D., Boddy A. V. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemother. Pharmacol. 2001; 47: 222–228, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yule S. M., Price L., McMahon A. D., Pearson A. D., Boddy A. V. Cyclophosphamide metabolism in children with non-Hodgkin’s lymphoma. Clin. Cancer Res. 2004; 10: 455–460, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yule S. M., Price L., Pearson A. D., Boddy A. V. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin. Cancer Res. 1997; 3: 1985–1992, [PUBMED], [INFOTRIEVE], [CSA]
- Yule S. M., Walker D., Cole M., McSorley L., Cholerton S., Daly A. K., Pearson A. D., Boddy A. V. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab. Dispos. 1999b; 27: 417–421, [PUBMED], [INFOTRIEVE], [CSA]
- Zaki E. L., Springate J. E., Taub M. Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells. Toxicol. In Vitro. 2003; 17: 397–402, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zemlickis D., Lishner M., Erlich R., Koren G. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog. Carcinog. Mutagen. 1993; 13: 139–143, [PUBMED], [INFOTRIEVE], [CSA]
- Zeng H., Bain L. J., Belinsky M. G., Kruh G. D. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 1999; 59: 5964–5967, [PUBMED], [INFOTRIEVE], [CSA]
- Zhang J., Tian Q., Chan S. Y., Duan W., Zhou S. F. Novel insights into the resistance to oxazaphosphorines and potential circumventing approaches. Drug Resist Update 2005, in press[CSA]
- Zhang Z. L., Georgiou H. M., Mandel T. E. The effect of cyclophosphamide treatment on lymphocyte subsets in the nonobese diabetic mouse: a comparison of various lymphoid organs. Autoimmunity 1993; 15: 1–10, [PUBMED], [INFOTRIEVE], [CSA]
- Zhao D., Jiang L., Hahn E. W., Mason R. P. Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology. Neoplasia 2005; 7: 678–687, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Zinzani P. L. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin. Oncol. 2005; 32: S4–10, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]